dacarbazine has been researched along with Glioma in 928 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.32) | 18.7374 |
| 1990's | 13 (1.40) | 18.2507 |
| 2000's | 299 (32.22) | 29.6817 |
| 2010's | 590 (63.58) | 24.3611 |
| 2020's | 23 (2.48) | 2.80 |
| Authors | Studies |
|---|---|
| Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Tresch, NS | 1 |
| Du, J; Li, S; Peng, C; Peng, F; Xie, X | 1 |
| Chen, Z; Lei, J; Sheng, C; Song, S; Zhu, G; Zhu, J | 1 |
| Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN | 1 |
| Garzio, K; Grossman, S; Holdhoff, M; McElroy, K; Ozer, B; Yankulina, O | 1 |
| Carpentier, A; Chinot, O; Cornu, P; Delattre, JY; Dufour, H; Emery, E; Faillot, T; Guillamo, JS; Guyotat, J; Hajage, D; Honnorat, J; Laigle-Donadey, F; Lebbah, S; Menei, P; Metellus, P; Paquis, P; Peruzzi, P; Proust, F; Wager, M | 1 |
| Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F | 1 |
| Chung, S; Huang, J; Sugimoto, Y; Zhang, M | 1 |
| Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M | 1 |
| Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y | 1 |
| Cai, L; Cao, X; Chen, Y; Chen, Z; Deng, M; Du, X; Guo, C; Hu, W; Hu, X; Jiang, T; Jiang, X; Ke, C; Li, C; Li, D; Li, G; Li, J; Li, X; Li, Z; Lin, F; Liu, J; Liu, M; Lv, X; Lv, Y; Mou, Y; Ni, X; Ouyang, H; Qin, Z; Sai, K; Su, J; Wang, H; Wang, J; Wang, Y; Wu, S; Xi, S; Xu, P; Xue, X; Yang, H; Yang, Q; Zeng, J; Zhang, J; Zhang, X; Zhong, S; Zhou, T | 1 |
| Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS | 1 |
| Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J | 1 |
| Grzywna, E; Krajcer, A; Lewandowska-Łańcucka, J | 1 |
| Arijs, I; Balvers, RK; Beerepoot, LV; Biswas, A; Byrne, AT; Chi Yen, RT; Connor, K; Dilcan, G; Dirven, CMF; Fabro, F; Idbaih, A; Jimenez-Cowell, K; Ju, J; Kers, TV; Kleijn, A; Klein, M; Kremer, A; Kros, JM; Lambrechts, D; Lamfers, MLM; Lawler, SE; Leenstra, S; Li, Y; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Stubbs, AP; van den Bent, MJ; Verreault, M | 1 |
| Alcaniz, J; Benesch, M; Birkl-Toeglhofer, AM; Golob-Schwarzl, N; Haybaeck, J; Hoffmann, J; Huber, HJ; Krassnig, S; Leber, SL; Leoni, M; Mahdy-Ali, K; Naumann, M; Orthmann, A; Pennauer, M; Raicht, A; Skofler, C; von Campe, G; Wälchli, T; Weis, S; Wohlrab, C | 1 |
| Ayala-Hernández, LE; Bosque, JJ; Chulián, S; Delobel, T; García-Ferrer, M; Murek, M; Pérez-Beteta, J; Pérez-García, VM; Piñero, P; Schucht, P | 1 |
| Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q | 1 |
| Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y | 1 |
| Han, Y; Jia, J; Liu, H; Lu, Y; Shen, J; Wang, L; Xu, H; Yu, R; Zhang, L; Zhao, Z | 1 |
| Alam, A; Mohile, N; Wasilewski, A | 1 |
| Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD | 1 |
| Anghileri, E; Fabi, A; Gaviani, P; Lanzetta, G; Lombardi, G; Pace, A; Pronello, E; Prosperini, L; Rizzato, S; Rudà, R; Scaringi, C; Simonetti, G; Targato, G; Villani, V | 1 |
| Friesen, C; Misch, M; Onken, J; Vajkoczy, P | 1 |
| Azzalin, A; Buffo, A; Garello, F; Magrassi, L; Nato, G; Parmigiani, E | 1 |
| Alattar, AA; Ali, MA; Brandel, MG; Carroll, KT; Carter, B; Chen, CC; Hirshman, B; Lanman, T; Lochte, B | 1 |
| Corbetta, C; Finocchiaro, G; Langella, T; Pellegatta, S | 1 |
| Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X | 1 |
| Jin, X; Lv, M; Sun, P; Tong, G; Wang, N; Zhu, X | 1 |
| Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q | 2 |
| Guan, Y; Qiu, B; Wang, Y; Wu, A; Zhang, D; Zhang, L | 1 |
| Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI | 1 |
| Liu, YG; Song, Y; Wang, HW; Xu, ZK | 1 |
| Bian, XW; Chen, X; Huang, N; Li, C; Li, H; Liu, S; Shen, HY; Wang, Y; Wu, N; Xiao, L; Yu, S | 1 |
| Grosch, J; Hänggi, D; Jung, E; Lemke, D; Osswald, M; Ratliff, M; Solecki, G; Weil, S; Wick, W; Winkler, F | 1 |
| Cerione, RA; Nakano, I; Rojas, K; Sullivan, KE; Wilson, KF | 1 |
| Roth, P; Silginer, M; Stupp, R; Weller, M | 1 |
| Cai, W; He, M; Li, K; Liu, A; Luo, M; Ouyang, L; Pi, R; Tu, Y | 1 |
| Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G | 1 |
| Cai, J; Han, B; Jiang, C; Li, J; Li, Z; Lin, L; Meng, X; Ming, J; Sun, B; Wang, R; Wu, P | 1 |
| Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W | 1 |
| Bielecka-Wajdman, AM; Lesiak, M; Ludyga, T; Obuchowicz, E; Sieroń, A | 1 |
| Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G | 1 |
| Chandler, J; Fountas, L; Grimm, S; Helenowski, I; Kumthekar, P; Levy, R; Marymont, M; McCarthy, K; Mehta, M; Muro, K; Raizer, J | 1 |
| Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI | 1 |
| Chen, Y; Gao, F; Hou, J; Jiang, R; Kang, L; Li, Y; Liu, H; Liu, X; Yang, M; Yi, Y | 1 |
| Chen, CH; Chen, CY; Chen, LY; Feng, LY; Hood, LE; Hsu, PW; Huang, WT; Wang, K; Wei, KC | 1 |
| Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M | 1 |
| Chen, J; Ding, L; Duan, Y; Huang, C; Li, R; Shen, M; Sun, Y; Wang, Q; Zhang, X | 1 |
| Lin, Z; Liu, H; Lu, J; Lue, S; Xu, Y; Yu, M; Zhang, H; Zhao, H | 1 |
| Batchelor, TT; Cahill, DP; Chi, AS; Fisher, DE; Higuchi, F; Iafrate, AJ; Koerner, MVA; Lelic, N; Miller, JJ; Shankar, GM; Tanaka, S; Tateishi, K; Wakimoto, H | 1 |
| Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G | 1 |
| Fukusumi, H; Goto, S; Handa, Y; Inazawa, Y; Kamigaki, T; Kanematsu, D; Kanemura, Y; Mori, K; Moriuchi, S; Nakajima, S; Nonaka, M; Okita, Y; Shofuda, T; Sumida, M; Takada, AI; Yamamoto, A; Yamasaki, M; Yoshioka, E | 1 |
| Abas, FS; Beattie, CE; Canella, A; Gumin, J; Gurcan, MN; Kaur, B; Kesanakurti, D; Lang, FF; Liu, J; Nagarajan, P; Puduvalli, VK; Sampath, D; Sulman, EP; Welker, AM; Xu, J; Yoo, JY | 1 |
| Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM | 1 |
| Chen, L; Cong, D; Hu, S; Li, Q; Li, Y; Wang, D | 1 |
| Brezzell, AL; Hervey-Jumper, SL; Kim, MM; Leung, D; Nathan, JK; Wilkinson, DA | 1 |
| Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL | 1 |
| Howard, TA; Villano, JL; Zhou, Z | 1 |
| Brennan, C; Chen, Z; Cimino, PJ; Hambardzumyan, D; Herting, CJ; Kaffes, I; Kaluzova, M; Park, JC; Pitter, KL; Szulzewsky, F; Wang, B | 1 |
| Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J | 1 |
| Amankulor, NM; Kim, WJ; Newman, WC | 1 |
| Aoki, K; Asai, N; Enomoto, A; Han, YP; Kato, A; Kato, T; Mii, S; Momota, H; Murakumo, Y; Natsume, A; Ogawa, S; Ohka, F; Shiraki, Y; Suzuki, H; Takahashi, M; Todo, T; Ushida, K; Wakabayashi, T | 1 |
| Hou, Y; Su, J; Wang, L; Wang, Z; Xia, J; Yan, J; Yin, X; Zhao, Z; Zheng, N; Zhou, X | 1 |
| Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M | 1 |
| Balcer, M; Belmans, J; Bouleti, C; De Vleeschouwer, S; Dejaegher, J; Georgieva, PB; Gerhardt, H; Mathivet, T; Matsumoto, K; Mazzone, M; Phng, LK; Sciot, R; Stanchi, F; Stockmann, C; Van Woensel, M; Verschuere, T | 1 |
| An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y | 1 |
| Adeberg, S; Bernhardt, D; Bougatf, N; Combs, SE; Debus, J; Haberer, T; Harrabi, SB; Herfarth, K; Paul, A; Rieken, S; Uhl, M; Unterberg, A; Verma, V; Wick, W | 1 |
| Chen, CH; Chen, KT; Cheng, YC; Chung, CY; Lee, IN; Lee, MH; Lu, FJ; Yang, JT | 1 |
| Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L | 1 |
| Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A | 1 |
| Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X | 1 |
| Deng, Y; Liu, Z; Wang, S; Xie, L; Zheng, M | 1 |
| Gorlia, T; Le Rhun, E | 1 |
| Carideo, L; Cicone, F; Mamede, M; Minniti, G; Russo, I; Scaringi, C; Scopinaro, F | 1 |
| Gupta, L; Gupta, U; Nakhate, KT; Qayum, A; Sahu, H; Sharma, AK; Singh, SK | 1 |
| Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF | 1 |
| Adamski, V; Chitadze, G; Flüh, C; Hattermann, K; Held-Feindt, J; Kabelitz, D; Synowitz, M | 1 |
| Ghia, AJ | 1 |
| Cohen, RJ; Mehta, MP | 1 |
| Hoang, N; Puduvalli, VK | 1 |
| Narita, Y | 1 |
| Drappatz, J; Lieberman, F | 1 |
| Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y | 1 |
| Chen, TC; Cho, HY; Hofman, FM; Marín-Ramos, NI; Schönthal, AH; Swenson, SD; Thein, TZ; Wang, W | 1 |
| Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC | 1 |
| Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN | 1 |
| Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC | 1 |
| Ahmed, AK; Jiang, Y; Li, Y; Lv, S; Wang, K; Xu, Q; Zhu, Y | 1 |
| Li, D; Li, X; Liu, ZQ; Pang, FM; Tan, D; Wu, J; Yan, H; Zhang, L | 1 |
| Franco, DG; Marie, SKN; Moretti, IF | 1 |
| Cheng, Y; Jin, W; Liu, H; Liu, N; Tu, Y; Wang, X; Wang, Z; Xu, X; Yang, H; Zhang, P; Zhang, Y | 1 |
| Chiou, SJ; Chou, CH; Chu, CW; Hong, YR; Hsiao, BX; Huang, WS; Loh, JK; Wang, YT; Yang, MC | 1 |
| Dai, B; Li, J; Qi, N; Zhang, G | 1 |
| Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H | 1 |
| Carvajal, S; Galvis, A; Giraldo, D; Loaiza, S; Ortiz, L | 1 |
| Chen, XG; Ji, M; Lai, FF; Lü, YH; Wang, LY | 1 |
| Hegazy, AM; Hirao, A; Ino, Y; Ito, C; Kasahara, A; Kobayashi, M; Nakada, M; Nomura, N; Peng, H; Tadokoro, Y; Takase, Y; Todo, T; Ueno, M; Vu, HT | 1 |
| Huang, J; Peng, Y; Shuai, X; Wu, T; Xiao, H | 1 |
| Bernal, G; Larsen, GF; Mansour, N; Nunez, L; Podell, M; Polster, SP; Yamini, B; Young, JS | 1 |
| Brancati, CIFO; Calastri, MCJ; Ferraz Filho, JRL; Godoy, MF; Gregório, ML; Hatori, G; Lancelloti, CLP; Neiva, CM; Rodrigues Junior, ACP; Rodrigues, NLTO; Souza, DRS; Tognola, WA; Zanovelo, EM | 1 |
| Lok, E; Swanson, KD; Wong, ET | 1 |
| Koike, H | 1 |
| Bai, YH; Bao, JJ; Chen, RK; Duan, WC; Liu, J; Liu, XZ; Wang, L; Wang, WW; Wang, YM; Yu, B; Zhan, YB; Zhang, FJ; Zhang, ZY; Zhao, XW; Zhou, JQ | 1 |
| Chen, MF; Cheng, CY; Wang, TC; Yang, WH | 1 |
| Chen, RM; Chio, CC; Liu, SH; Mohanraj, M; Tai, YT; Yang, ST | 1 |
| Day, PJ; Fung, CF; Ho, AS; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Zhang, XQ | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Baron, MH; Bauchet, L; Beauchesne, P; Blonski, M; Darlix, A; Duffau, H; Fabbro, M; Fontaine, D; Gozé, C; Mandonnet, E; Pallud, J; Peruzzi, P; Rigau, V; Taillandier, L | 1 |
| Auf, G; Bayerl, SH; Broggini, T; Bruenner, J; Czabanka, M; Harms, C; Harms, U; Heppner, FL; Jabouille, A; Koch, A; Kremenetskaia, I; Mueller, S; Nieminen, M; Parmaksiz, G; Topalovic, M; Vajkoczy, P | 1 |
| Kanno, H; Kohsaka, S; Tanaka, S | 1 |
| Miyakita, Y; Momota, H; Narita, Y; Shibui, S | 1 |
| Braunsdorf, WE; Giese, A; Gutenberg, A; Lumenta, CB; Mehdorn, HM; Sabel, M; Westphal, M | 1 |
| Kruser, TJ; Mehta, MP; Robins, HI | 1 |
| Adams, S; Ahrendt, T; Bode, HB; Guillemin, GJ; Oezen, I; Opitz, CA; Platten, M; Radlwimmer, B; Sahm, F; von Deimling, A; Wick, W | 1 |
| Chen, LC; Du, WZ; Feng, Y; Jiang, CL; Jiang, T; Li, RY; Li, XF; Li, YL; Liu, X; Sun, Y; Wang, HB; Wen, JQ; Yang, DB; Zhang, HY | 1 |
| Sun, J; Yang, SY; Yang, XJ | 1 |
| Dharmalingam, K; Kumar, DM; Nila, MV; Patil, V; Ramachandran, B; Somasundaram, K | 1 |
| Chen, FR; Chen, ZP; Sai, K; Wang, J | 1 |
| Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Bashamboo, A; Berthaut, I; Deluen, F; Dessolle, L; McElreavey, K; Montjean, D; Morcel, K; Poirot, C; Ravel, C | 1 |
| Attinà, G; Bertolini, P; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Migliorati, R; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A | 1 |
| Becker, KA; Gramatzki, D; Gulbins, E; Happold, C; Herrmann, C; Tabatabai, G; Weller, M | 1 |
| Aftab, Q; Chen, VC; Gielen, PR; Hong, X; Lozinsky, S; Ma, N; Naus, CC; Sin, WC | 1 |
| Agarwal, S; Al-Keilani, MS; Alqudah, MA; Assem, M; Ryken, TC; Sibenaller, ZA | 1 |
| Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N | 1 |
| Araki, N; Hide, T; Hirayama, M; Kobayashi, D; Komohara, Y; Kuratsu, J; Makino, K; Midorikawa, U; Mizuguchi, S; Nagai, M; Nagayama, M; Nakamura, H; Niibori-Nambu, A; Takeya, M; Takezaki, T; Tsubota, N | 1 |
| Boxhammer, V; Klämpfl, TG; Köritzer, J; Li, YF; Morfill, GE; Schäfer, A; Schlegel, J; Schwenk-Zieger, S; Shimizu, T; Welz, C; Zimmermann, JL | 1 |
| Christiansen, H; Kortmann, RD; Kramm, CM; Müller, K; Schlamann, A; Seidel, C; von Bueren, AO; Vordermark, D; Warmuth-Metz, M | 1 |
| Gupta, T; Jalali, R; Mohanty, S; Moiyadi, A | 1 |
| Darabi, A; Eberstål, S; Fritzell, S; Sandén, E; Siesjö, P; Visse, E | 1 |
| Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C | 1 |
| Bernal, GM; Cahill, KE; Kang, S; LaRiviere, MJ; Larsen, GF; Mansour, N; Noriega, SE; Nunez, L; Pytel, P; Spretz, R; Voce, DJ; Weichselbaum, RR; Welp, U; Yamini, B | 1 |
| Lukas, RV; Nicholas, MK | 1 |
| Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H | 1 |
| Adachi, K; Hayashi, T; Hirose, Y; Ohba, S | 1 |
| Chen, YS; Chen, ZP; Feng, BH; Guo, CC; Qiu, ZK; Shen, D; Yang, QY | 1 |
| Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS | 1 |
| Bailey, S; Boota, N; Connolly, DJ; Fisher, D; Gibson, M; Glaser, A; Hargrave, D; Howman, A; Kearns, P; Picton, S; Pizer, B; Saran, F; Wheatley, K; Wherton, D | 1 |
| Fan, X; Li, X; Ni, S; Qi, H; Wang, J | 1 |
| Bigner, DD; Dechkovskaia, AM; Dodd, RD; Dusto, NL; Epple, LM; Graner, MW; Herring, M; Lencioni, AM; Madsen, H; Merz, AL; Nega, M; Nicchitta, CV; Russell, RL; Serkova, NJ; White, J; Winston, BA | 1 |
| Beier, D; Girbinger, V; Holm, PS; Lage, H; Mantwill, K; Mittelbronn, M; Naumann, U; Schlegel, J; Seznec, J; Surowiak, P | 1 |
| Jin, Z; Xu, S; Yang, B; Yu, H; Zhao, G; Zhao, H | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL | 1 |
| Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J | 1 |
| Airenne, K; Alasaarela, L; Määttä, AM; Pikkarainen, J; Samaranayake, H; Stedt, H; Ylä-Herttuala, S | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Condorelli, G; De Marinis, P; Diaz-Lagares, A; Donnarumma, E; Esteller, M; Fiore, D; Iaboni, M; Mangani, D; Quintavalle, C; Romano, G; Roscigno, G; Soini, Y | 1 |
| Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L | 1 |
| Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C | 1 |
| Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P | 1 |
| Bosma, I; Buter, J; de Groot, M; Douw, L; Froklage, FE; Heimans, JJ; Klein, M; Lagerwaard, FJ; Oosterbaan, LJ; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Uitdehaag, BM | 1 |
| Chen, B; Liu, XY; Ming, ZJ; Ren, YJ; Wang, J; Wu, J; Yang, JM; Yang, WQ; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Hu, JA; Shen, W; Zheng, JS | 1 |
| Aburatani, H; Aihara, K; Asthana, S; Barnes, M; Berger, MS; Bollen, AW; Cha, S; Chang, SM; Charron, E; Costello, JF; Fouse, SD; Gustafson, WC; Hirst, M; Hong, C; Jalbert, LE; Johnson, BE; Jones, SJM; Marra, MA; Mazor, T; McLean, CY; Moore, RA; Mukasa, A; Mungall, AJ; Nelson, SJ; Olshen, AB; Saito, N; Smirnov, IV; Song, JS; Tatsuno, K; Taylor, BS; Ueda, H; Weiss, WA; Yamamoto, S; Zhao, Y | 1 |
| Hernández-Pedro, NY; Magaña-Maldonado, R; Manoutcharian, K; Pérez-De la Cruz, V; Pineda, B; Rangel-López, E; Rodríguez-Balderas, C; Sotelo, J | 1 |
| Chinot, O; Crétel, E; Retornaz, F; Rousseau, F; Tabouret, E; Tassy, L | 1 |
| Kapoor, S; Padhi, R; Rallabandi, VP; Roy, PK; Sakode, C | 1 |
| Dhermain, F | 1 |
| Ho, YK; Low, SY; Ng, WH; Too, HP; Yap, CT | 1 |
| Cho, BJ; Choi, EJ; Chun, SH; Hwang, YH; Kim, HH; Kim, IA; Lee, DJ | 1 |
| Basso, ME; Bertin, D; Fagioli, F; Mussano, A; Pittana, LS; Vallero, SG | 1 |
| Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS | 2 |
| Jang, JD; Jeong, CH; Jeun, SS; Kim, SM; Ryu, CH; Woo, JS | 1 |
| Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M | 1 |
| Dong, DF; Gao, K; Wang, JB; Wang, MD | 1 |
| Ito, M; Kato, K; Kato, Y; Motomura, A; Motomura, K; Natsume, A; Ohka, F; Ranjit, M; Saito, K; Senga, T; Soga, T; Wakabayashi, T | 1 |
| Case, D; Dietrich, AM; Duncan, SE; Harmon, M; Lesser, G; Mirlohi, S | 1 |
| Glück, A; Guckenberger, M; Kortmann, RD; Kramm, C; Müller, K; Pietschmann, S; Schlamann, A; von Bueren, AO; Warmuth-Metz, M; Wawer, A | 1 |
| Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; DeSilva, A; Han, SJ; Molinaro, AM; Prados, MD; Rolston, JD | 1 |
| Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S | 1 |
| Balyasnikova, IV; Chang, AL; Cheng, Y; Dey, M; Han, Y; Kim, CK; Kim, JW; Lesniak, MS; Qiao, J; Tobias, A; Wainwright, DA; Zhang, L | 1 |
| Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY | 1 |
| Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ | 1 |
| Brügge, D; Hottinger, A; Hundsberger, T; Putora, PM; Roelcke, U; Stupp, R; Tonder, M; Weller, M | 1 |
| Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y | 1 |
| Bähr, O; Fischer, S; Fulda, S; Harter, PN; Kögel, D; Mittelbronn, M; Paschke, R; Reichert, S; Ronellenfitsch, MW; Steinbach, JP; Thiepold, AL; Weller, M | 1 |
| Lebrun-Frenay, C | 1 |
| Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM | 1 |
| Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X | 1 |
| Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y | 1 |
| Cui, XL; Li, HL; Lin, S; Zhang, JN | 1 |
| Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X | 1 |
| Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC | 1 |
| Chen, QD; Ge, X; Jiang, BH; Jiang, CF; Li, DM; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, ZM; Wang, L; Wang, XF; You, YP | 1 |
| Fang, W; Hu, Z; Li, Z; Liu, Z; Long, H; Peng, Y; Qi, S; Que, T; Song, Y; Wang, G; Yi, L; Zhang, X; Zheng, S | 1 |
| Chen, TC; Cho, HY; Dubeau, L; Hofman, FM; Jhaveri, N; Lee, DJ; Schönthal, AH; Sharma, N; Wang, W | 1 |
| Athawale, R; Bajaj, A; Goel, PN; Gude, R; Jain, D; Nikam, Y; Patil, S; Prashant Raut, P; Shrikhande, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W | 1 |
| Mukherjee, J; Ohba, S; Pieper, RO; See, WL | 1 |
| Jo, J; Lopes, MB; Schiff, D; Shaffrey, ME; Smolkin, M; Williams, B; Wintermark, M | 1 |
| Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ | 1 |
| Ge, N; Gong, A; Liang, H; Lu, L; Yao, W | 1 |
| Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ | 2 |
| Taal, W; van den Bent, MJ | 1 |
| Beveridge, RD; Carroll, TA; Collis, SJ; Cox, A; Depondt, ML; Fernando, M; Jellinek, D; Kriplani, DH; Myers, KN; Patil, AA; Roylance, A; Sayal, P | 1 |
| Chen, H; Fang, J; Han, C; Lan, J; Lou, M; Wu, Z; Xue, Y; Zhao, S | 1 |
| Han, S; Li, Z; Master, LM; Master, ZW; Wu, A | 1 |
| Fukai, J; Koizumi, F; Nakao, N | 1 |
| Bonnet, P; Cartron, PF; Cheray, M; Nadaradjane, A; Routier, S; Vallette, FM | 1 |
| Akers, J; Bao, ZS; Carter, B; Chen, CC; Chen, HM; Fan, XL; Hu, BQ; Hu, HM; Jiang, T; Kang, CS; Li, J; Li, MY; Li, RQ; Liu, YW; Qiu, XG; Ramakrishnan, V; Song, WS; Su, XD; Wang, Z; Yan, W; Yang, MY; Yao, K; Ye, WL; You, YP; Yu, K; Zhang, CB; Zhang, W | 1 |
| Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G | 1 |
| Hyodo, A; Nagaishi, M; Sugiura, Y; Suzuki, K; Takano, I; Tanaka, Y; Yokoo, H | 1 |
| Castro, GN; Cayado-Gutiérrez, N; Ciocca, DR; Cuello-Carrión, FD; Fanelli, MA; Nadin, SB; Sottile, M; Zoppino, FC | 1 |
| Du, B; Li, HY; Ma, JW; Wang, SX; Xie, SM; Ye, JC; Zhang, Y; Zhong, XY | 1 |
| Rees, J | 1 |
| Chapet, S; Lévy, S; Mazeron, JJ | 1 |
| Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y | 1 |
| Bauman, G; Cao, J; Ferguson, M; Rodrigues, G | 1 |
| Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H | 1 |
| Cai, T; Chen, YD; Liao, F; Liu, Q; Wang, ZF; Wu, H | 1 |
| Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J | 1 |
| Chen, J; Cui, D; Ni, L; Shi, J; Shi, W; Sun, B; Zuo, H | 1 |
| Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA | 1 |
| Chai, KM; Fang, KM; Liaw, HJ; Tzeng, SF; Wang, CY; Yang, CS | 1 |
| Liang, H; Xing, BZ; Yang, WB | 1 |
| Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S | 1 |
| Du, J; Gao, Y; Gong, H; Shi, H; Tang, Y; Wang, L; Wu, Y; Yu, R; Zheng, B | 1 |
| Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB | 1 |
| Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P | 1 |
| Li, P; Liu, H; Qian, C; Shi, L; Wang, Y; Yan, W; You, Y; Zhang, J | 1 |
| Dempsey, RJ; Kuo, JS; Pointer, KB; Zhang, RR | 1 |
| Guo, M; Hu, S; Shen, L; Zhang, X | 1 |
| Bennett, CL; DeBoer, R; Deeb, M; Fisher, MJ; Fitzner, KA; Grimm, SA; Haleem, MS; Jacobs, DI; Liebling, DB; Luu, TH; McKoy, JM; Raizer, JJ; Ray, PS; Trifilio, SM; Tulas, KM | 1 |
| Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M | 1 |
| Chen, JY; Chen, PY; Huang, CY; Liu, HL; Wang, HY; Wei, KC | 1 |
| Anton, M; Holm, PS; Kostova, Y; Mantwill, K | 1 |
| Huo, L; Tang, G; Wu, J; Xiao, G | 1 |
| Akiyama, Y; Hori, YS; Horio, Y; Hosoda, R; Kuno, A; Maruyama, M; Mikami, T; Mikuni, N; Sebori, R; Sugino, T; Suzuki, K; Tsukamoto, M; Wanibuchi, M | 1 |
| He, W; Liu, R; Yang, SH; Yuan, F | 1 |
| Bernaudin, M; Divoux, D; Gérault, AN; Guillamo, JS; Pérès, EA; Petit, E; Roussel, S; Sanson, M; Toutain, J; Valable, S | 1 |
| Cheng, JT; Chou, AK; Chou, CH; Hong, YR; Howng, SL; Huang, WS; Li, YY; Lieu, AS; Loh, JK; Wang, YT; Yang, MC | 1 |
| Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z | 1 |
| Chen, A; Chen, S; Chen, W; Du, X; He, Y; Huang, B; Li, X; Ma, C; Qu, X; Shao, Q; Wang, D; Zhao, P | 1 |
| Chicoine, MR; Dacey, RG; DeWees, TA; Dowling, JL; Huang, J; Kim, AH; Leuthardt, EC; Linette, G; Rich, KM; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD; Zipfel, GJ | 1 |
| Wang, Q; Wang, W; Zou, Y | 1 |
| Bhardwaj, RD; Nakaji, P; Ponce, FA; Rosenfeld, A; Xu, DS | 1 |
| Bian, LG; Cai, S; Liu, W; Pan, SJ; Pan, YX; Sun, B; Sun, QF; Wu, YB | 1 |
| Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M | 1 |
| Bendszus, M; Blaes, J; Heiland, S; Hertenstein, A; Jestaedt, L; Kessler, T; Milford, D; Osswald, M; Pfenning, PN; Platten, M; Rübmann, P; Ruiz de Almodóvar, C; Sahm, F; Urban, S; von Deimling, A; Weiler, M; Wick, A; Wick, W; Winkler, F | 1 |
| Gu, Y; Liu, J; Ma, L; Qi, J; Yu, W; Zhang, X | 1 |
| Bueno e Silva, MM; Filippi-Chiela, EC; Lenz, G; Thomé, MP | 1 |
| Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B | 1 |
| Liu, L; Zhang, M | 1 |
| Bernard, B; Cogdell, DE; Fuller, GN; Granberg, KJ; Hu, L; Ji, P; Nykter, M; Shmulevich, I; Sun, Y; Turner, KM; Yli-Harja, O; Yung, WK; Zhang, W; Zhou, X | 1 |
| Elhag, R; Mazzio, EA; Soliman, KF | 1 |
| Ampie, L; Kusne, Y; Sanai, N | 1 |
| Dong, Y; He, H; Lu, Y; Luo, C; Tao, B; Wang, C; Wang, L; Xiang, J; Yu, X; Zhao, Z; Zhou, H | 1 |
| Ding, WX; Gu, L; Guo, XW; Huang, XE; Liu, YC; Yin, XX; Zhou, SB | 1 |
| Balyasnikova, IV; Bernal, GM; Cahill, KE; Crawley, CD; Larsen, GF; Mansour, NM; Nunez, L; Spretz, R; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W | 1 |
| Belloli, S; Bosari, S; Diceglie, C; Gianelli, U; Lo Dico, A; Lucignani, G; Martelli, C; Moresco, RM; Ottobrini, L; Politi, LS; Raccagni, I; Vaira, V; Valtorta, S | 1 |
| Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G | 1 |
| Chai, H; Chen, H; Chen, X; Duan, C; Li, Y; Qin, T; Tang, T; Wang, C; Yang, J; Yue, J; Zhang, J; Zhang, X | 1 |
| Jancalek, R; Kazda, T; Laack, NN; Pospisil, P; Prochazka, T; Sevela, O; Slampa, P; Vrzal, M | 1 |
| Schiff, D | 2 |
| Adesina, A; Chintagumpala, M; Eckel, SP; Gajjar, A; Krailo, M; Lau, C; Morris, M; Packer, R | 1 |
| Cui, L; Gu, X; Li, K; Li, Y; Liang, W; Ma, G; Wang, X; Xiao, H; Zhao, B; Zhou, H | 1 |
| Balvers, RK; Berghauser Pont, LM; Dirven, CM; Kleijn, A; Kloezeman, JJ; Lamfers, ML; Leenstra, S | 1 |
| Beier, CP; Beier, D; Fosmark, S; Hellwege, S; Kristensen, BW; Sørensen, MD | 1 |
| Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS | 1 |
| Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF | 1 |
| Levin, VA | 1 |
| Rinne, ML; Wen, PY | 1 |
| Ashcraft, KA; Boss, MK; Choudhury, KR; Dewhirst, MW; Keir, ST | 1 |
| Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW | 1 |
| Fujiwara, H; Hirose, Y; Katayama, M; Kimura, T; Kitamura, Y; Ohira, T; Sasaki, H; Toda, M; Yazaki, T; Yoshida, K | 1 |
| Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY | 1 |
| Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD | 1 |
| Banković, J; Dinić, J; Hadžić, S; Isaković, A; Paunović, V; Pešić, M; Podolski-Renić, A; Stanković, T; Stojković, S; Tanić, N | 1 |
| Arfuso, F; Bhuvanalakshmi, G; Dharmarajan, A; Millward, M; Warrier, S | 1 |
| Butz, L; Dittmann, K; Huber, SM; Klumpp, L; Ruth, P; Stegen, B; Zips, D | 1 |
| Chie, EK; Cho, BJ; Choi, EJ; Eom, KY; Kim, IA; Kim, IH; Kim, JH; Kim, JS; Paek, SH; Wu, HG | 1 |
| Altin, D; Bardal, T; Berg, K; Ellingsen, PG; Gederaas, OA; Hauge, A; Høgset, A; Lindgren, M | 1 |
| Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK | 1 |
| Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ | 1 |
| Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J | 1 |
| Boldorini, R; Buosi, R; Gaudino, E; Mancuso, G; Mercalli, F; Mezzapelle, R; Miglio, U; Paganotti, A; Rena, O; Veggiani, C | 1 |
| Bai, QL; Hu, CW; Li, WL; Lv, YM; Ren, BW; Wang, XR; Yin, GF; Zhang, WG; Zhao, WQ | 1 |
| Bastian, A; Gangjee, A; Ihnat, M; Pavana, RK; Saunders, D; Smith, N; Towner, RA | 1 |
| Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G | 1 |
| Dong, Y; He, H; Hu, G; Li, S; Li, Y; Liu, F; Lu, Y; Luo, C; Meng, Y; Tao, B; Yao, M; Zhang, C; Zhang, W; Zong, H | 1 |
| Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z | 1 |
| Du, J; Mao, G; Song, S; Zhu, X | 1 |
| Fan, Y; Lv, S; Wu, M; Xiao, B; Ye, M; Zhu, X | 1 |
| Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J | 1 |
| Awaji, M; Boman, BM; Endo, S; Fields, JZ; Hayakawa, Y; Kozano, H; Kurimoto, M; Kuroda, S; Ogata, T; Sugimori, M; Tamura, R; Yamada, M; Yamamoto, S | 1 |
| Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S | 1 |
| Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY | 1 |
| Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W | 1 |
| Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L | 1 |
| Lu, P; Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhou, D | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T | 1 |
| Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y | 1 |
| Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D | 1 |
| Du Four, S; Duerinck, J; Everaert, H; Hau, P; Michotte, A; Neyns, B; Sander, W; Van Binst, AM | 1 |
| Chen, HM; Guan, DG; Liao, SF; Zhao, TZ | 1 |
| Kouri, FM; Ritner, C; Stegh, AH | 1 |
| Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R | 1 |
| Ananta, JS; Massoud, TF; Paulmurugan, R | 1 |
| Crippa, F; Galldiks, N; Hofer, S; Nowosielski, M; Roelcke, U; Roth, P; Rudà, R; Soffietti, R; Weller, M; Wyss, MT | 1 |
| Azevedo, H; Moreira-Filho, CA | 1 |
| Field, KM; Khasraw, M; Nowak, AK; Rosenthal, MA; Sawkins, K | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Ji, X; Kang, J; Liu, F; Liu, K; Liu, X; Luo, Y; Wen, S; Zeng, X; Zhao, S | 1 |
| Hanihara, M; Kawataki, T; Kinouchi, H; Mitsuka, K; Nakao, A; Oh-Oka, K | 1 |
| An, P; Chi, XY; Long, B; Tian, Y; Tong, DY; Wu, XY; Zhang, LM; Zhao, XC | 1 |
| Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hock, S; Savaskan, NE; Sehm, T; Yakubov, E | 1 |
| Agasse, F; Armstrong, D; Chen, L; Chen, TC; Commins, D; Hofman, FM; Jhaveri, N; Peng, L; Rosenstein-Sisson, R; Santiago, SV; Santos, T; Schönthal, AH; Vaikari, VP; Wang, W | 1 |
| Benderitter, M; Bernier, MO; Brochet, B; Delattre, JY; Douzane, H; Durand, T; Feuvret, L; Hoang-Xuan, K; Jacob, S; Lebouil, L; Leclercq, D; Lestaevel, P; Milliat, F; Noël, G; Psimaras, D; Rahimian, A; Ricard, D; Tamarat, R; Vayatis, N | 1 |
| Bianchi, N; Borgatti, M; Breveglieri, G; Brognara, E; Cabrini, G; Corradini, R; Dechecchi, MC; Fabbri, E; Finotti, A; Gambari, R; Gasparello, J; Lampronti, I; Manicardi, A; Milani, R; Montagner, G | 1 |
| Cao, Y; Sun, J; Yang, X; Zhang, W | 1 |
| Choi, KH; Park, M; Song, C; Yoon, H | 1 |
| Gao, S; Hao, B; Hong, B; Jiang, C; Li, J | 1 |
| Chen, Q; Han, J | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E; Tosoni, A | 1 |
| Bégué, RE; Deputy, S; Toler, J; Zakris, E | 1 |
| Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K | 1 |
| Dang, X; Hu, J; Wang, G; Wang, J; Yao, Z | 1 |
| Álvarez de Eulate-Beramendi, S; Álvarez-Vega, MA; Balbin, M; Martino-González, J; Sanchez-Pitiot, A; Vallina-Alvarez, A | 1 |
| Alizadeh, D; Badie, B; Berlin, JM; Chen, X; Da Fonseca, A; Gao, H; Guo, Q; Manuel, ER; Ouyang, M; Ren, H; Shah, S; Vonderfecht, SL; Weng, Y; White, EE; Yanyan, S; Zhang, I; Zhang, L | 1 |
| Chen, K; Chen, TC; Groshen, SL; Hofman, FM; Jhaveri, N; Kota, R; Kushal, S; Olenyuk, BZ; Shih, JC; Vaikari, VP; Wang, W; Yeh, TS | 1 |
| Aldaz, P; Arrizabalaga, O; Barrena, C; Carrasco-Garcia, E; Garcia, I; Garros-Regulez, L; Lovell-Badge, R; Manterola, L; Matheu, A; Moncho-Amor, V; Moreno-Cugnon, L; Pollard, S; Ruiz, I; Sampron, N; Villanua, J | 1 |
| Jiang, T; Li, MY; Li, WB; Liu, YW; Peng, XX; Qiu, XG; Wang, KY; Wang, YY; Wang, YZ; Yang, P; Yao, K; Zhang, CB; Zhang, W | 1 |
| Casey, A; Conway, GE; Cullen, PJ; Curtin, JF; Howe, O; Liu, Y; Milosavljevic, V | 1 |
| Chao, ME; Chen, W; Chu, SS; Ho, DM; Hsieh, TH; Liang, ML; Lin, SC; Liu, DJ; Liu, RS; Liu, YR; Ng, KH; Tsai, CF; Tsai, YN; Wang, HW; Wong, TT; Yang, MH | 1 |
| Gatto, F; Nielsen, J | 1 |
| Cabrera, I; De Cola, L; Maggini, L; Prasetyanto, EA; Robinet, E; Ruiz-Carretero, A | 1 |
| Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T | 1 |
| Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T | 1 |
| Wang, E; Wu, F; Yu, G | 1 |
| Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE | 1 |
| Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H | 1 |
| Hsieh, YJ; Hsu, CW; Huang, CW; Huang, YM; Hung, TY; Sze, CI; Wu, SJ; Wu, SN; Yeh, PS | 1 |
| Al-Sarraj, S; Bridges, LR; Burford, A; Carceller, F; Fowkes, LA; Hovestadt, V; Jerome, N; Jones, C; Jones, DT; Khabra, K; Koh, DM; Laxton, R; Leach, MO; Mackay, A; Mandeville, H; Marshall, LV; Moreno, L; Pearson, AD; Pfister, SM; Saran, F; Vaidya, S; Zacharoulis, S | 1 |
| Fenstermaker, RA; Mechtler, LL; Morr, S; Prasad, D; Qiu, J | 1 |
| Du, J; Liu, J; Wang, J; Wang, Q; Wang, X; Xu, B; Xu, L | 1 |
| Cai, Y; Liu, P; Zhao, W; Zhu, J | 1 |
| Botelho, RV; de Oliveira, MF; Reis, RC; Rotta, JM | 1 |
| Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S | 1 |
| Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR | 1 |
| Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR | 1 |
| Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F | 1 |
| Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z | 1 |
| Billimek, J; Bota, DA; Lee, B; Nolen, SC; Shantharam, S; Su, L; Yu, HJ | 1 |
| Blankenstein, MA; Buter, J; de Groot, M; Heimans, JJ; Holla, FK; Klein, M; Postma, TJ; Reijneveld, JC; Sizoo, EM; Uitdehaag, BMJ; van Mierlo, TJM; Vos, MJ | 1 |
| Chen, ZY; Liu, YW; Qi, ST; Wang, H; Xiang, W; Xie, SD; Yi, GZ | 1 |
| Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y | 1 |
| Cai, Z; Hu, G; Hu, L; Liang, Q; Lu, Y; Wang, Q; Zhang, C | 1 |
| Fan, X; Lan, T; Qu, Y; Song, Y; Wang, H; Yu, C; Zhan, Q; Zhang, M; Zhang, Z; Zhao, Z; Zhou, W | 1 |
| Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML | 1 |
| Bian, LG; Jiang, H; Liu, W; Pan, SJ; Pan, YX; Sun, B; Sun, QF; Zhan, SK | 1 |
| Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M | 1 |
| Castro, MG; Doherty, R; Lowenstein, PR; Wilson, TJ; Zamler, DB | 1 |
| Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M | 1 |
| Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W | 1 |
| Engel, D; Flüh, C; Hattermann, K; Held-Feindt, J; Mehdorn, HM; Mentlein, R; Synowitz, M | 1 |
| Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K | 1 |
| Berte, N; Eich, M; Kaina, B; Kim, E; Lokan, S | 1 |
| Hou, CX; Wang, P; Ye, JA; Zhan, SQ; Zhou, D | 1 |
| Hertenstein, A; Platten, M; Wick, W | 1 |
| Braga, C; Brites, D; Bronze, MR; Falcão, AS; Moreira, R; Perry, MJ; Pinheiro, R; Santos, G | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T | 1 |
| Baumert, BG; Hegi, ME; Hottinger, AF | 1 |
| Bao, S; Dong, L; Wang, M; Wu, Y; Yun, Y; Zhu, R | 1 |
| Back, M; Baumert, BG; Borchers, C; Bottomley, A; Brandes, AA; Bromberg, JEC; Chinot, O; Coens, C; Enting, RH; Golfinopoulos, V; Gorlia, T; Hassel, MB; Hau, P; Hoang-Xuan, K; Kantor, G; Klein, M; Mason, WP; Reijneveld, JC; Reni, M; Ryan, G; Smits, A; Stupp, R; Taphoorn, MJB; Thiessen, B; Verger, E; Wick, A | 1 |
| Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W | 1 |
| Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T | 1 |
| Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G | 1 |
| Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V | 1 |
| Dai, X; Lan, Q; Ma, C; Xu, T | 1 |
| Cisneros Castillo, LR; Oancea, AD; Régnier-Vigouroux, A; Stüllein, C | 1 |
| Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E | 1 |
| Gao, YF; Li, L; Liu, ZQ; Liu, ZX; Mao, CX; Mao, XY; Wang, ZB; Yin, JY; Zhou, HH; Zhu, T | 1 |
| Blondin, N; Chaudhry, A; Connelly, J; Hormigo, A; Hu, J; Mohilie, N | 1 |
| Fan, B; Jiao, BH; Jing, SY; Sun, GZ; Tong, J; Wang, F; Yang, JK; Yang, JP | 1 |
| Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X | 1 |
| Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET | 1 |
| Gao, S; Liang, J; Wang, W; Wang, Y | 1 |
| Baer, C; Blaes, J; Claus, R; Felsberg, J; Galldiks, N; Grimm, C; Hartmann, C; Hau, P; Hertenstein, A; Hielscher, T; Meisner, C; Pietsch, T; Plass, C; Platten, M; Reifenberger, G; Roth, P; Sabel, MC; Sahm, F; Schackert, G; Schliesser, MG; Schmidt-Graf, F; Schramm, J; Vajkoczy, P; von Deimling, A; Weichenhan, D; Weiler, M; Weiß, EK; Weller, M; Westphal, M; Wick, W; Wiestler, B; Winkler, F | 1 |
| Araki, H; Kuwabara, Y; Ohue, S; Suehiro, S; Tanaka, A; Tanaka, M; Watanabe, S; Yamashita, D | 1 |
| Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W | 1 |
| Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM | 1 |
| Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S | 1 |
| Di, H; Du, J; Sun, S; Wang, J; Wang, Q; Wang, X; Xu, B; Xu, X | 1 |
| Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A | 1 |
| Augustin, HG; Bae, J; Han, S; He, Y; Kim, C; Kim, I; Kim, IK; Kim, JH; Koh, GY; Lee, D; Lee, S; Oh, SJ; Park, I; Park, JS; Woo, DC | 1 |
| Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shen, WL; Shih, CM | 1 |
| Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F | 1 |
| Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D | 1 |
| Aldape, KD; Batchelor, TT; Chang, SM; Chen, A; Cloughesy, TF; de Groot, J; DeAngelis, LM; Drappatz, J; Fisher, J; Gilbert, MR; Grossman, S; Lieberman, F; Nayak, L; Omuro, A; Prados, M; Wefel, JS; Wen, PY; Ye, X; Yung, AW | 1 |
| Cheng, L; Fu, J; Guo, Y; Liao, Y; Liu, Q; Peng, R; Shen, L; Zhao, H | 1 |
| Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS | 1 |
| Luedtke, NW; Marsoner, T; Schmidt, OP; Triemer, T | 1 |
| Bahassi, EM; Chan, TA; Chu, Z; Koncar, RF; Qi, X; Romick-Rosendale, LE; Wells, SI | 1 |
| Du, FY; Ge, L; Gong, AH; Han, X; Jin, J; Peng, WX; Zhang, CL | 1 |
| Bautista, W; Ewend, MG; Frady, LN; Gilbert, MR; Kwintkiewicz, J; Liu, Y; Lu, Y; MacDonald, J; Moon, SI; Su, YT; Tech, K; Wu, J; Yang, C | 1 |
| Chamberlain, MC; Colman, H; Kim, BT; Raizer, J | 1 |
| Beck, J; Belmonte-Beitia, J; Bodnar, M; Bogdańska, MU; Murek, M; Pérez-García, VM; Schucht, P | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Zhang, C; Zhang, XJ | 1 |
| Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK | 1 |
| Ben Abdallah, M; Blonski, M; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S | 1 |
| Asad, AS; Candolfi, M; Castro, MG; Chandran, M; Koschmann, C; Lowenstein, PR; Mineharu, Y; Shah, D; Yadav, VN | 1 |
| Hottinger, AF; Stupp, R | 1 |
| Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Navalitloha, Y; Siangprasertkij, C | 1 |
| Chiamchanya, S; Dhanachai, M; Hongeng, S; Laothamatas, J; Pakakasama, S; Sirachainan, N; Tuntiyatorn, L; Visudithbhan, A | 1 |
| Guiot, MC; Huang, F; Kavan, P; Markovic, Y; Roberge, D | 1 |
| Akimoto, J; Kobayashi, I; Oka, H; Tanaka, S; Ujiie, H | 1 |
| Ashley, DM; Dobrovic, A; Drummond, KJ; Friedman, HS; Gan, HK; Hawkins, CJ; Johns, TG; Kaye, AH; Lovric, MM; Maxwell, JA; Mikeska, T; Riffkin, CD | 1 |
| Chamberlain, MC | 2 |
| Nagane, M | 2 |
| Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A | 1 |
| Barnes, J; Dellagatta, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, NR; Sauvageot, CM; Stiles, CD; Weatherbee, JL; Wen, PY; Winters, SE | 1 |
| D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S | 1 |
| Dario, A; Tomei, G | 1 |
| Cashman, R; Morrison, M; Morrison, T; Perry, JR; Rizek, P | 1 |
| Geisert, EE; Kang, GS; Kirichenko, OV; Miller, DD; Mohler, ML; Orr, WE; Patil, R; Wang, XD | 1 |
| Platten, M; Weller, M; Wick, W | 1 |
| Brandes, AA; Dietrich, PY; Hottinger, AF; Stupp, R; van den Bent, MJ | 1 |
| Baumert, BG; Stupp, R | 2 |
| Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D | 1 |
| Cordera, S; Joosens, E; Nader, P; Neyns, B; Pouratian, N | 1 |
| Ancheta, K; Chtchetinin, J; Cloughesy, T; Lai, A; Nghiemphu, PL; Remington, M | 1 |
| Broniscer, A; Ellison, D; Kasow, K; Morris, EB; Reiss, U | 1 |
| Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T | 1 |
| Patel, R; Shervington, A | 1 |
| Speer, TW | 1 |
| Gallo, JM; Zhou, Q | 1 |
| Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N | 1 |
| Eisele, G; Happold, C; Linnebank, M; Roth, P; Steinbach, JP; Weller, M; Wick, W | 1 |
| Classon, M; Hingtgen, S; Ren, X; Shah, K; Terwilliger, E; Weissleder, R | 1 |
| Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S | 1 |
| Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM | 1 |
| Chamberlain, MC; Raizer, J | 1 |
| Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D | 1 |
| Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE | 1 |
| Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY | 1 |
| Garrett-Mayer, E; Giglio, P; Herrin, AE; Jenrette, JM; Marshall, DT; Patel, S; Watkins, JM | 1 |
| Chaskis, C; De Ridder, M; Everaert, H; Michotte, A; Neyns, B | 1 |
| Aikawa, E; Chen, JW; Figueiredo, JL; McCann, CM; Waterman, P; Weissleder, R | 1 |
| Armstrong, TS; Bondy, M; Cao, Y; Gilbert, MR; Manning, R; Okcu, MF; Scheurer, ME; Vera-Bolaños, E; Zhou, R | 1 |
| de Groot, J; LaFortune, T; Milano, V; Piao, Y | 1 |
| Amoroso, R; Bartoli, B; Benvenuti, L; Gagliardi, R; Gremigni, V; Lena, A; Rechichi, M; Rossi, L; Salvetti, A; Scarcelli, V; Vecchio, D | 1 |
| Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A | 2 |
| Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W | 1 |
| Banissi, C; Carpentier, AF; Chen, L; Ghiringhelli, F | 1 |
| Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W | 1 |
| Fujii, M; Ito, M; Natsume, A; Ohno, M; Wakabayashi, T | 1 |
| Persson, AI; Weiss, WA | 1 |
| Bleau, AM; Brennan, CW; Fomchenko, EI; Hambardzumyan, D; Holland, EC; Huse, JT; Ozawa, T | 1 |
| Hop, WC; Jeurissen, FJ; Roon, K; Taphoorn, MJ; Vecht, CJ; Zwinkels, H | 1 |
| Han, Y; Khramtsov, A; Lesniak, MS; Nandi, S; Sonabend, AM; Ulasov, IV | 1 |
| Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR | 1 |
| Bell, D; Khasraw, M; Wheeler, H | 1 |
| Méhes, G; Molnár, P | 1 |
| Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J | 1 |
| Buchsbaum, DJ; Gillespie, GY; Grizzle, WE; Harmon, DK; Kaliberov, SA; Kaliberova, LN; Krendelchtchikova, V; Markert, JM; Petersen, AS; Stockard, CR | 1 |
| Ducray, F | 1 |
| Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W | 1 |
| Lesser, GJ; Ruiz, J | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Chang, S; Heimberger, A; McCoy, L; Patil, C; Patoka, J; Prados, M; Rice, T; Sampson, JH; Schwartzbaum, J; Wiemels, JL; Wiencke, JK; Wilson, D; Wrensch, M | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K | 1 |
| Lesniak, MS; Tyler, MA; Ulasov, IV | 1 |
| Chen, M; Orlow, SJ; Osman, I | 1 |
| Campion, L; Cartron, PF; Charbord, J; Debien, E; Hervouet, E; Menanteau, J; Vallette, FM | 1 |
| Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P | 1 |
| Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Sano, H | 1 |
| Bressler, LR; Seery, TE; Villano, JL | 1 |
| Cevenini, G; Marsili, S; Miracco, C; Mourmouras, V; Oliveri, G; Pirtoli, L; Rubino, G; Tini, P; Vannini, M | 1 |
| Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG | 1 |
| Wakabayashi, T | 1 |
| Banerjee, A; Dinca, EB; Gupta, N; Hashizume, R; James, CD; Ozawa, T; Prados, MD | 1 |
| Gong, F; Ji, SP; Li, AM; Tai, JL; Zhang, YP; Zheng, CQ | 1 |
| Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R | 1 |
| Estlin, EJ; McGown, A; Najim, N; Podmore, ID | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R | 1 |
| Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, TS | 1 |
| Brandsma, D; van den Bent, MJ | 2 |
| Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F | 1 |
| Baron, MH; Bauchet, L; Bernier, V; Capelle, L; Duffau, H; Fontaine, D; Guyotat, J; Mandonnet, E; Pallud, J; Peruzzi, P; Taillandier, L | 1 |
| Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD | 1 |
| DeAngelis, LM | 2 |
| Bamberg, M; Engel, C; Ernemann, U; Felsberg, J; Hartmann, C; Ketter, R; Koeppen, S; Kortmann, RD; Meisner, C; Meyermann, R; Pietsch, T; Rapp, M; Reifenberger, G; Sabel, MC; Stockhammer, F; Stoffels, M; von Deimling, A; Weller, M; Wick, W; Wiestler, OD | 1 |
| Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H | 1 |
| Lavini, C; Majoie, CBLM; Reijneveld, JC; Richel, DJ; Stalpers, LJA; van Furth, WR; van Linde, ME; Verhoeff, JJC | 1 |
| Athanasios, K; Gousias, K; Konstantinos, G; Kyritsis, A | 1 |
| Weller, M | 2 |
| Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A | 1 |
| Cruickshanks, N; Munje, C; Patel, R; Shervington, A; Shervington, L; Thakkar, D | 1 |
| Chang, FC; Chang, KP; Chen, YW; Chiang, KL; Hsu, TR; Huang, PI; Lee, YY; Wong, TT | 1 |
| Wen, PY | 1 |
| Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B | 1 |
| Agha, CA; Elias, DA; Fathallah-Shaykh, HM; Hassan, A; Ibrahim, S | 1 |
| Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T | 1 |
| Aird, E; Bar-Deroma, R; Baumert, BG; Bernard Davis, J; Collette, L; Fenton, P; Gulyban, A; Musat, E; Roelofs, E; Stupp, R; Weber, DC | 1 |
| Hattermann, K; Held-Feindt, J; Lucius, R; Mentlein, R; Müerköster, SS; Penfold, ME; Schall, TJ | 1 |
| Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Kawamoto, K; Li, Y; Numa, Y; Oishi, T; Oshige, H; Yamahara, T; Zhen, Y | 1 |
| Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Anderson, WS; Dunn, I; Norden, A; Sure, D | 1 |
| Ballman, KV; Carlson, BL; Decker, PA; Giannini, C; Kitange, GJ; Morlan, BW; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E | 1 |
| Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S | 1 |
| Jean-Claude, BJ; Rachid, Z; Watt, HL | 1 |
| Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M | 1 |
| Choe, G; Kim, CY; Kim, HJ; Kim, IA; Kim, JH; Kim, KJ; Kim, WH; Kim, YJ; Lee, MM; Yoon, SH | 1 |
| Brada, M; Pentheroudakis, G; Stupp, R; Tonn, JC | 1 |
| Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A | 1 |
| Kögel, D; Lang, V; Ronellenfitsch, MW; Seifert, V; Senft, C; Steinbach, JP; Voss, V | 1 |
| Brat, DJ; Burger, PC; Cohen, KJ; Finlay, JL; Gilles, FH; Hamilton, RL; Jakacki, RI; LaFramboise, WA; Lyons-Weiler, MA; Nikiforov, YE; Nikiforova, MN; Pollack, IF; Rosenblum, MK; Sobol, RW; Yates, AJ; Zhou, T | 1 |
| Beauchamp, DC; Blough, MD; Cairncross, JG; Kelly, JJ; Westgate, MR | 1 |
| Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R | 1 |
| Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH | 1 |
| Chen, J; Pan, T; Shi, L; Wang, Z; Yang, J; Zhang, S | 1 |
| Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U | 1 |
| Bracci, PM; McCoy, LS; Patoka, JS; Rice, T; Sison, JD; Wiemels, JL; Wiencke, JK; Wrensch, MR; Zhou, M | 1 |
| Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A | 1 |
| Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC | 1 |
| Mariani, L; Ochsenbein, AF; Schubert, AD; Vassella, E | 1 |
| Ellsworth, R; Hsieh, A; Hsieh, D | 1 |
| Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH | 1 |
| Bailey, SM; Darley-Usmar, VM; Diers, A; Gillespie, GY; Griguer, CE; Landar, A; Markert, JM; McClugage, SG; Nozell, SE; Oliva, CR; Sarkaria, JN | 1 |
| Abacioglu, U; Akgun, Z; Atasoy, BM; Caglar, HB; Sengoz, M; Yumuk, PF | 1 |
| Kern, BC; Krex, D; Mehdorn, HM; Nestler, U; Pichlmeier, U; Stockhammer, F; Stummer, W; Vince, GH | 1 |
| Albanese, A; Anile, C; Apicella, G; Azario, L; Balducci, M; Cellini, N; Chiesa, S; D'Agostino, GR; de Bonis, P; Dinapoli, N; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Valentini, V | 1 |
| Berg, A; Kolesar, J; Mehta, M; Petrich, RJ; Steen, P; Sylvester, RK; Tate, JM | 1 |
| Boisselier, B; Delattre, JY; Guillevin, R; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laffaire, J; Laigle-Donadey, F; Mokhtari, K; Paris, S; Sanson, M; Wang, X | 1 |
| Belka, C; Ertl, L; Ganswindt, U; Geisler, J; Kreth, FW; la Fougère, C; Linn, J; Niyazi, M; Schwarz, SB; Siefert, A; Tonn, JC | 1 |
| Lefebvre, G; Poirot, C; Prades, M; Sanson, M; Schubert, B; Sitbon Sitruk, L | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| D'Avella, D; Fassan, M; Gardiman, MP; Onisto, M; Perilongo, G; Tassone, E | 1 |
| Slotman, BJ; Van Den Berg, J; van Nifterik, KA; Van Rijn, J | 1 |
| Chattopadhyay, P; Chosdol, K; Gupta, D; Jain, A; Jha, P; Pathak, P; Sarkar, C; Sharma, MC; Srivastava, A; Suri, A; Suri, V | 1 |
| Fujita, M; Okada, H; Snyder, LA; Zhu, X | 1 |
| Fan, X; Liu, Y; Ni, S; Qi, H; Wang, C; Wang, X | 1 |
| Elandt, K; Heinzl, H; Marosi, C; Preusser, M; Schwarzinger, I | 1 |
| Balsamo, T; Barbano, R; Carella, M; Catapano, D; Coco, M; Copetti, M; D'Angelo, V; Fazio, VM; Icolaro, N; la Torre, A; Merla, G; Muscarella, LA; Notarangelo, A; Parisi, S; Parrella, P; Pellegrini, F; Troiano, M; Valori, VM | 1 |
| Connor, JR; Hong, YS; Lee, SY; Liu, S; Mitchell, RM; Sheehan, JM; Slagle-Webb, B | 1 |
| Adair, J; Kiem, HP; Mrugala, MM | 1 |
| Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK | 1 |
| Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY | 1 |
| Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N | 1 |
| Chansriwong, P; Sirisinha, T | 1 |
| Aoki, T; Hashimoto, N; Kayama, T; Natsume, A; Nishikawa, R; Ogura, M; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T; Yoshida, J | 1 |
| Gao, L; Huang, F; Li, Q; Liu, Y; Luan, S; Mao, Y; Zhang, H; Zhuang, D | 1 |
| Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN | 1 |
| Chen, TC | 1 |
| Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S | 1 |
| Alcaide-German, M; Bourne, S; Giampieri, S; Lio, KI; Martindale, C; Shaked-Rabi, M; Short, SC; Sioftanos, G; Worku, M | 1 |
| Egensperger, R; Eigenbrod, S; Hinske, LC; Kreth, FW; Kreth, S; Kretzschmar, HA; Ledderose, C; Lutz, J; Thon, N; Tonn, JC | 1 |
| Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F | 1 |
| Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH | 1 |
| Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H | 1 |
| Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S | 1 |
| Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR | 1 |
| Kyritsis, AP; Levin, VA | 1 |
| Baumer, B; Keefer, LK; Koentges, C; Kogias, E; Osterberg, N; Papazoglou, A; Psarras, N; Saavedra, JE; Weyerbrock, A | 1 |
| Etcheverry, A; Hamlat, A; Lesimple, T; Mosser, J; Quillien, V; Saikali, S; Vauléon, E | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Lawrence, YR; Mehta, M; Michalski, JM; Souhami, L; Wang, M; Yung, WK | 1 |
| Cuneo, KC; Desjardins, A; Friedman, HS; Kirkpatrick, JP; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Willett, CG | 1 |
| Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X | 1 |
| Ichikawa, M; Kurokawa, M; Nakamura, F; Nannya, Y; Ogura, M; Tanaka, M; Todo, T | 1 |
| Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH | 1 |
| Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK | 1 |
| Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN | 1 |
| Akiyoshi, K; Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Kimura, M; Manome, Y; Nomura, M; Saito, H; Saito, Y; Somura, H | 1 |
| Demopoulos, A; Nandipati, S | 1 |
| Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W | 1 |
| Bradshaw, TD; Hummersone, M; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Barnes, J; Fast, EM; Keating, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, N; Veldhuijzen van Zanten, SE; Zawel, L; Ziegler, DS | 1 |
| Jing, Z; Qiu, B; Wang, Y; Wu, A; Zhang, D | 1 |
| Motomura, K; Natsume, A; Wakabayashi, T | 1 |
| Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ | 1 |
| Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X | 1 |
| Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S | 1 |
| Hirose, Y | 1 |
| Berkhof, J; Bosma, I; Buter, J; Heimans, JJ; Hoekstra, OS; Lagerwaard, FJ; Noske, DP; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Vos, MJ | 1 |
| Bauchet, L; Beauchesne, P; Blonski, M; Campello, C; Duffau, H; Fabbro, M; Gozé, C; Herbet, G; Kerr, C; Maldonado, IL; Moritz-Gasser, S; Rigau, V; Rudà, R; Soffietti, R; Taillandier, L | 1 |
| Boström, J; Glas, M; Herrlinger, U; Kim, Y; Mack, F; Rieger, J; Schäfer, N; Scheffler, B; Simon, M; Steinbach, JP; Stuplich, M; Thanendrarajan, S; Tichy, J | 1 |
| Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Aguilar, LK; Aguilar-Cordova, E; Baskin, DS; Bell, SD; Cavaliere, R; Chakravarti, A; Chiocca, EA; Grecula, J; Grossman, RG; Hardcastle, J; Harris, KS; Kaur, B; Lo, S; Manzanera, AG; McGregor, J; Monterroso, C; New, PZ; Newton, H; Ray-Chaudhuri, A; Trask, TW | 1 |
| Brower, V | 1 |
| Dong, XT; Li, JM; Li, Y; Pan, Q; Wang, HM; Wang, W; Yang, XJ | 1 |
| Gillespie, GY; Griguer, CE; Moellering, DR; Oliva, CR | 1 |
| Das, UN; Faragó, N; Fehér, LZ; Kitajka, K; Puskás, LG | 1 |
| Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Ishizawa, S; Kimura, M; Manome, Y; Saito, H | 1 |
| Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE | 1 |
| Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G | 1 |
| Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J | 1 |
| Desjardins, A; Sampson, JH | 1 |
| Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA | 1 |
| Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Pu, P; Zhang, A; Zhang, C; Zhang, J; Zheng, Y | 1 |
| van den Bent, MJ | 2 |
| Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Liu, Y; Pu, P; Shi, Z; Zhang, K; Zheng, Y | 1 |
| Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH | 1 |
| Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F | 1 |
| Bageritz, J; Barbus, S; Becker, N; Danner, A; Dittmann, LM; Felsberg, J; Goidts, V; Gronych, J; Grzendowski, M; Lichter, P; Reifenberger, G; Sabel, MC; Stühler, K; Tews, B; Toedt, G; Wolter, M | 1 |
| Tu, Q; Wang, L; Zhou, R; Zhou, W | 1 |
| Enger, PØ; Leiss, L; Li, X; Skaftnesmo, KO; Sleire, L; Wang, J; Yan, T | 1 |
| Packer, RJ | 1 |
| Qiu, B; Tian, A; Wang, M; Wu, A; Xue, X; Zhang, D | 1 |
| Hattermann, K; Held-Feindt, J; Mentlein, R | 1 |
| Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q | 1 |
| Gu, K; Wang, J; Zhai, X; Zhang, J | 1 |
| Brandal, P; Dahlback, HS; Håvik, AB; Heim, S; Hektoen, M; Helseth, E; Honne, H; Lind, GE; Lothe, RA; Meling, TR; Scheie, D | 1 |
| Berkutzki, T; Cooper, I; Mohar, B; Ruban, A; Teichberg, VI | 1 |
| Bromberg, JE; Kros, JM; Segers-van Rijn, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CC; van Heuvel, I | 1 |
| Bertholle, V; Billard, M; Borget, I; Brignone, M; Cartalat, S; Charlety, D; Chinot, O; Exinger, D; Gensollen, S; Hassani, Y; Labrande, C; Lahille, B; Pedeboscq, S; Pinguet, F; Prebay, D; Taillibert, S; Tilleul, P | 1 |
| Jensen, SA; Kouri, FM; Stegh, AH | 1 |
| Combs, SE; Debus, J; Haberer, T; Habermehl, D; Jaekel, O; Rieken, S | 1 |
| Kaina, B; Marosi, C; Neyns, B; Strik, HM | 1 |
| Brodie, C; Brown, SL; Golembieski, WA; King, DA; Rempel, SA; Schultz, CR | 1 |
| Ling, Y; Wei, K; Zhong, S; Zou, F | 1 |
| Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y | 1 |
| Abe, S; Azuma, A; Fujita, K; Gemma, A; Hayashi, H; Kobayashi, K; Kokuho, N; Morimoto, T; Saito, Y; Tanaka, T | 1 |
| Bar-Deroma, R; Baumert, BG; Fairchild, A; Fenton, PA; Gulyban, A; Stupp, R; Weber, DC | 1 |
| Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS | 1 |
| Bonizzoni, E; Detti, B; Fabrini, MG; Lolli, I; Paccapelo, A; Perrone, F; Perrone, T; Santoni, M; Savio, G; Scoccianti, S; Silvano, G | 1 |
| Barceló-Coblijn, G; Busquets, X; Escribá, PV; García-Verdugo, JM; Gómez-Pinedo, U; Higuera, M; Lladó, V; Marcilla-Etxenike, A; Martin, ML; Noguera-Salvà, MA; Saus, C; Soriano-Navarro, M; Terés, S | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Franz, K; Güresir, E; Oszvald, Á; Quick, J; Seifert, V; Szelényi, A; Vatter, H | 1 |
| Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K | 1 |
| Gavrilovic, IT; Kaley, TJ; Mondesire-Crump, I | 1 |
| Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
| Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS | 1 |
| Fernández de Mattos, S; Ramis, G; Rodríguez, J; Thomàs-Moyà, E; Villalonga, P | 1 |
| Chen, TH; Lee, CC; Lin, CH; Lin, CJ; Shih, CM; Shih, YL; Wang, SH | 1 |
| Engh, JA; Faraji, AH; Horowitz, M; Lunsford, LD; Park, DM | 1 |
| Boxerman, J; Jeyapalan, S; Raghavan, D; Rogg, J | 1 |
| Li, S; Xie, Q; Zhang, W; Zheng, X | 1 |
| Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Cortes, U; Karayan-Tapon, L; Marquant, C; Martin, S; Rivet, P; Tourani, JM; Turhan, AG; Villalva, C; Wager, M | 1 |
| Baker, L; Dixit, S; Hingorani, M; Walmsley, V | 1 |
| Kang, C; Long, L; Pu, P; Qian, X; Ren, Y; Sheng, J; Shi, Z; Yuan, X | 1 |
| Akers, J; Carter, BS; Carvajal, I; Chakravarti, A; Chen, CC; Furfine, E; Futalan, D; Gonda, DD; Marsh, N; Morse, B; Palanichamy, K; Sahin, A; Sanchez, C; Scheer, JK; Waterman, P; Waters, JD; Weissleder, R | 1 |
| Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS | 1 |
| Matsko, MV | 1 |
| Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC | 1 |
| Ducray, F; Lekoubou, A; Viaccoz, A | 1 |
| Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK | 1 |
| Bleeker-Rovers, CP; De Vos, FY; Gijtenbeek, JM; van Herpen, CM | 1 |
| Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T | 1 |
| Bagriacik, EU; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Ozet, A; Uslu, K; Yaman, M | 1 |
| Geng, J; Luo, H; Pu, Y; Wu, X; Xu, W; Yang, Z; Zhou, Z | 1 |
| Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M | 1 |
| Miyakita, Y; Nagai, S; Narita, Y; Ohno, M; Okita, Y; Shibui, S | 1 |
| Alonso-Llamazares, A; Beitia-Mazuecos, JM; Cardenas-Contreras, R; Mateo-Borrega, B; Vega-Castro, A | 1 |
| Kawai, N; Miyake, K; Okada, M; Shinomiya, A; Tamiya, T | 1 |
| Chen, R; Chen, W; Chou, AP; Cloughesy, T; Deng, Y; Everson, RG; Faull, KF; Lai, A; Li, S; Liau, LM; Lou, JJ; Phillips, HS; Selfridge, J; Wu, KC; Zurayk, M | 1 |
| Cong, ZX; Ji, XJ; Li, N; Li, WC; Pan, H; Wang, HD; Wang, JW; Zhou, Y; Zhu, L | 1 |
| De Sanctis, V; Di Stefano, D; Enrici, RM; Esposito, V; Falco, T; Lanzetta, G; Minniti, G; Scaringi, C | 1 |
| Frishman, C; Marrinan, J; Sampath, P; Sengupta, S | 1 |
| Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E | 1 |
| Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y | 1 |
| Chen, LY; Han, L; Kang, CS; Liu, CY; Pu, PY; Qian, XM; Shi, ZD; Yuan, XB; Zhang, JX; Zhang, KL | 1 |
| Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA | 1 |
| Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C | 1 |
| Aguilera, DG; Esiashivilli, N; Hayes, L; Janns, A; Jordan, C; Macdonald, TJ; Mazewski, C | 1 |
| Chen, FR; Chen, ZP; Li, C; Shao, CJ; Wu, MW; Xia, YF | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hoffman, RM; Momiyama, M; Suetsugu, A | 1 |
| Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J | 1 |
| Chen, J; Hu, G; Lu, Y; Luo, C; Qian, J; Wang, J; Wang, Q | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Blackwood, R; Brown, M; Harmon, M; Lesser, G; Lovato, J; Strowd, RE; Yalcinkaya, T | 1 |
| Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M | 1 |
| Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR | 1 |
| Jiang, R; Li, X; Sun, J; Wang, Z; Yang, S; Yang, W; Yang, X; Yue, S; Zhang, J; Zhu, T | 1 |
| Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E | 1 |
| Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K | 1 |
| Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V | 1 |
| Christmann, M; Kaina, B; Knizhnik, AV; Nikolova, T; Quiros, S; Roos, WP; Tomaszowski, KH | 1 |
| Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E | 1 |
| Danson, SJ; Middleton, MR | 1 |
| Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S | 1 |
| Bhakat, KK; Bocangel, DB; Finkelstein, S; Kokkinakis, DM; Mitra, S; Schold, SC | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH | 1 |
| Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F | 1 |
| Gaya, A; Greenstein, A; Rees, J; Stebbing, J | 1 |
| Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL | 1 |
| Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G | 1 |
| Arnold, H; Damasceno, R; Günther, W; Pawlak, E; Terzis, AJ | 1 |
| Affronti, ML; Avgeropoulos, N; Bigner, DD; Evans, B; Finlay, J; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K | 1 |
| Baayen, HC; Barkhof, F; Boogerd, W; Castelijns, JA; Elkhuizen, PH; Heimans, JJ; Postma, TJ; Uitdehaag, BM; Vos, MJ | 1 |
| Berger, MS; Erickson, LC; Hirose, Y; Kreklau, EL; Pieper, RO | 1 |
| Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA | 1 |
| Chou, TC; Dong, HJ; Figul, M; Rainov, NG; Söling, A | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Chamberlain, M; Glantz, M; Litofsky, NS; Liu, Q; Recht, LD | 1 |
| Aboagye, EO; Brady, F; Brock, CS; Brown, GD; Jones, T; Luthra, SK; Newlands, E; Osman, S; Price, P; Ranicar, AS; Saleem, A; Stevens, MF | 1 |
| Finlay, JL; Knopp, EA; Kuo, DJ; Miller, DC; Weiner, HL; Wisoff, J | 1 |
| Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK | 1 |
| Foster, T; Newlands, ES; Zaknoen, S | 1 |
| Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S | 1 |
| Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M | 1 |
| Brown, P; Buckner, J | 1 |
| Fouladi, M; Gajjar, AJ; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF | 1 |
| Dolan, ME; Nagasubramanian, R | 1 |
| Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P | 1 |
| Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A | 1 |
| Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y | 1 |
| Germano, IM; Ito, H; Kanzawa, T; Komata, T; Kondo, S; Kondo, Y | 1 |
| Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P | 1 |
| Buster, WP; Gruber, ML | 1 |
| Chinot, OL | 1 |
| Abson, C; Brada, M; Dzik-Jurasz, AS; Leach, MO; Murphy, PS; Rowland, IJ; Viviers, L | 1 |
| Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A | 1 |
| Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK | 1 |
| Ashley, DL; Cher, L; Rosenthal, MA | 2 |
| Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R | 1 |
| Berger, MS; Hirose, Y; Katayama, M; Pieper, RO | 1 |
| Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC | 1 |
| Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ | 1 |
| Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A | 1 |
| de Bruin, HG; de Wit, MC; Eijkenboom, W; Sillevis Smitt, PA; van den Bent, MJ | 1 |
| Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Carpentier, AF | 1 |
| Golubnitschaja, O; Haertel, N; Moenkemann, H; Schüller, H; Trog, D | 1 |
| Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R | 1 |
| Cairncross, JG; Mymryk, JS; Xu, GW | 1 |
| Leyvraz, S; Ostermann, S; Stupp, R; Wasserfallen, JB | 1 |
| Brandes, AA; Lonardi, S; Tosoni, A | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 2 |
| Ashley, S; Brada, M; Dowe, A; Gonsalves, A; Huchet, A; Pesce, G; Reni, M; Saran, F; Wharram, B; Wilkins, M; Wilkins, P | 1 |
| Akasaki, Y; Black, KL; Das, A; Khong, HT; Liu, G; Wheeler, CJ; Yu, JS | 1 |
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Cao, Y; Chenevert, TL; Kessler, ML; Lawrence, TS; Shen, Z; Tatro, DS; Ten Haken, R; Tsien, CI | 1 |
| Beardsley, NJ; Glickson, JD; Mancuso, A; Pickup, S; Wehrli, S; Zhu, A | 1 |
| Cavallo, G; Crinò, L; Esposti, RD; Foschini, MP; Franceschi, E; Marliani, AF; Paioli, A; Paioli, G; Palmerini, E; Scopece, L | 1 |
| Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I | 1 |
| Bouffet, E; Foreman, N; Korones, DN; Smith, A | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Holland, EC; Momota, H; Nerio, E | 1 |
| Hatano, H; Ishii, D; Mizuno, M; Natsume, A; Tsuno, T; Wakabayashi, T; Yoshida, J | 1 |
| Comella, P; Formato, R; Iaffaioli, RV; Muto, P; Pisano, A; Quattrin, S; Tafuto, S; Tortoriello, A | 1 |
| Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA | 1 |
| Bigner, DD; Birch, R; Brem, H; Dancey, JE; Delaney, SM; Desjardins, A; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Maxwell, J; McLendon, RE; Moschel, RC; Pegg, AE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, J; Sampson, JH; Tourt-Uhlig, S; Vredenburgh, J; Weingart, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Nakada, M | 1 |
| Sawamura, Y | 1 |
| Takahashi, H; Tanaka, R; Uzuka, T | 1 |
| Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD | 1 |
| Chaskis, C; De Ridder, M; Keyaerts, M; Michotte, A; Neyns, B; Sadones, J; Veld, PI | 1 |
| Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A | 1 |
| Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS | 1 |
| Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K | 1 |
| Chan, DT; Chan, YL; Ng, HK; Poon, WS | 1 |
| Ashley, D; Cher, L; Dowling, A; Jennens, R; Rosenthal, MA; Wong, S; Woods, AM | 1 |
| Barbarisi, M; Moraci, A; Moraci, M; Parlato, C | 1 |
| Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A | 1 |
| Benouaich-Amiel, A; Delattre, JY | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A | 1 |
| Itasaka, S; Kim, JT; Lee, JI; Nam, DH | 1 |
| Fountoulakis, M; Friedlein, A; Golubnitschaja, O; Trog, D | 1 |
| Avis, T; Barthorpe, S; Batchelor, TT; Bignell, G; Brackenbury, L; Buck, G; Butler, A; Cahill, DP; Clements, J; Cole, J; Davies, H; Dicks, E; Easton, DF; Edkins, S; Forbes, S; Futreal, PA; Gorton, M; Gray, K; Greenman, C; Halliday, K; Harrison, R; Hills, K; Hinton, J; Hunter, C; Jenkinson, A; Jones, D; Kosmidou, V; Laman, R; Levine, KK; Louis, DN; Lugg, R; Menzies, A; Mueller, W; O'Meara, S; Parker, A; Perry, J; Petty, R; Raine, K; Richardson, D; Riggins, G; Roy, JE; Shepherd, R; Small, A; Smith, R; Solomon, H; Stephens, P; Stevens, C; Stratton, MR; Teague, J; Tofts, C; Varian, J; West, S; Widaa, S; Wooster, R; Yates, A | 1 |
| Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK | 1 |
| Capelle, L; Duffau, H; Taillandier, L | 1 |
| Blümcke, I; Buslei, R; Eyüpoglu, IY; Fahlbusch, R; Hahnen, E; Lemke, D; Savaskan, NE; Siebzehnrübl, FA; Tränkle, C; Wick, W | 1 |
| Eoh, W; Kang, CM; Kim, JS; Kim, JT; Kim, MH; Ko, KW; Kong, DS; Lee, DS; Nam, DH; Shin, HJ; Son, MJ; Song, HS | 1 |
| Abuja, B; Deinsberger, R; Hassler, M; Marosi, C; Micksche, M; Payer, F; Pichler, J; Stockhammer, G | 1 |
| Breipohl, W; Fountoulakis, M; Friedlein, A; Golubnitschaja, O; Haertel, N; Leppert, D; Moenkemann, H; Schild, H; Schueller, H; Trog, D; Yeghiazaryan, K | 1 |
| Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W | 1 |
| Frank, B; Möhle, R; Tabatabai, G; Weller, M; Wick, W | 1 |
| Natsume, A; Wakabayashi, T; Yoshida, J | 1 |
| Barnett, CM; Brock, C; Bydder, GM; Charnley, N; Glaser, M; Matthews, J; Newlands, ES; Price, P; Swindell, R; West, CM | 1 |
| Hong, YK; Jeun, SS; Kang, JK; Kim, MC; Kim, MK; Lee, KS; Lee, TK; Park, CK; Yang, SH | 1 |
| Wong, ET | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Mutter, N; Stupp, R | 1 |
| Berger, MS; Katayama, M; Kawaguchi, T; Pieper, RO | 1 |
| Mabasa, VH; Taylor, SC | 1 |
| Auger, N; Dutrillaux, B; Idbaih, A; Legrier, ME; Poupon, MF; Sanson, M; Thillet, J; Wanherdrick, K | 1 |
| Gao, S; Zhang, H | 1 |
| Aimar, E; Banna, GL; Bettio, D; Colombo, P; Gaetani, P; Navarria, P; Rodriguez Baena, R; Rognone, F; Santoro, A; Scorsetti, M; Simonelli, M | 1 |
| Azcoaga Blasco, JM; Contreras Martínez, J; Delgado Rico, R; Herruzo Cabrera, I; Rivas Sánchez, D; Villanueva Alvarez, A; Wals Zurita, A | 1 |
| Breipohl, W; Golubnitschaja, O; Moenkemann, H; Schild, H; Schueller, H; Trog, D | 1 |
| Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH | 1 |
| Hong, YK; Joe, YA; Kim, TG; Park, JA | 1 |
| Gerber, DE; Grossman, SA; Kleinberg, L; Parisi, MA; Zeltzman, M | 1 |
| Norden, AD; Wen, PY | 1 |
| Alonso, MM; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y | 1 |
| Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y | 1 |
| Chen, ZP; Mu, YG; Sai, K; Shi, HL; Yue, WY; Zhang, JP; Zhang, XH | 1 |
| Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J | 1 |
| Nishikawa, R | 1 |
| Chen, CC; D'Andrea, A; Taniguchi, T | 1 |
| Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B | 1 |
| Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q | 1 |
| Hirose, Y; Sano, H | 1 |
| Delattre, JY; Sanson, M | 1 |
| Laigle-Donadey, F; Sanson, M | 1 |
| Jones, B; Sanghera, P | 1 |
| Bauer, B; Bogdahn, U; Brenner, A; Hau, P; Hundsberger, T; Jauch, T; Koch, D; Koch, H; Marg, E; Rauch, M; Rieckmann, P; Rudolph, R; Schuth, J | 1 |
| Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G | 1 |
| Fehlauer, F; Muench, M; Rades, D; Richter, E | 1 |
| Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA | 1 |
| Dalmau, J; de la Fuente, BP; Rosenfeld, M | 1 |
| Aghi, M; Martuza, RL; Rabkin, S | 1 |
| Germano, IM; Keller, G; Uzzaman, M | 1 |
| Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S | 1 |
| Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ | 1 |
| Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S | 1 |
| DeAngulo, G; Heimberger, AB; Hussain, SF; Jordan, JT; Prabhu, SS; Sun, W | 1 |
| Akagi, T; Aoyanagi, E; Kaneko, S; Sasai, K; Tabu, K; Tanaka, S | 1 |
| Alemany, R; Alonso, MM; Bekele, NB; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y; Yung, WK | 1 |
| Fujii, M; Ishii, D; Ito, M; Maruta, H; Natsume, A; Shimato, S; Wakabayashi, T; Yoshida, J | 1 |
| Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J | 1 |
| Gerrard, G; Khanduri, S | 1 |
| Chalmers, AJ; Yu, SK | 1 |
| Hong, YK; Kim, CH; Kim, HS; Kim, TG; Park, JS; Park, MY; Park, SD; Woo, SJ | 1 |
| Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Crott, R | 1 |
| Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P | 1 |
| Fan, XJ; Fu, YJ; Liang, AH; Liu, ZL; Xu, CG; Xu, QL; Yang, J; Yin, LT | 1 |
| Asano, Y; Fujii, M; Hatano, H; Ishii, D; Ito, M; Natsume, A; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J | 1 |
| Nieder, C | 1 |
| Daido, S; Iwado, E; Kondo, S; Kondo, Y | 1 |
| Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K | 1 |
| Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X | 1 |
| Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Price, A; Rogers, G; Somerville, M; Stein, K | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT | 1 |
| Alonso, MM; Bekele, BN; Fueyo, J; Gomez-Manzano, C; Yung, WK | 1 |
| Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA | 1 |
| Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Mizoguchi, M; Shono, T | 1 |
| Chakravarti, A; Palanichamy, K | 1 |
| Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M | 1 |
| Katayama, Y; Yoshino, A | 1 |
| da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G | 1 |
| Bontempi, G; Debeir, O; Decaestecker, C; Haibe-Kains, B; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Mijatovic, T | 1 |
| Gallo, JM; Guo, P; Zhou, Q | 1 |
| Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
| Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Kleinberg, LR; Lin, SH | 1 |
| Choi, JD; Friedman, AH; Powers, CJ; Sampson, JH; Vredenburgh, JJ | 1 |
| Fang, SH; Huang, XJ; Li, CT; Lu, YB; Wei, EQ; Zhang, WP | 1 |
| Kawase, T; Sasaki, H; Yoshida, K | 1 |
| Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A | 1 |
| Fu, W; Geiger, GA; Kao, GD | 1 |
| Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC | 1 |
| Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ | 1 |
| Apel, MA; Battastini, AM; Braganhol, E; Canedo, AD; da Frota, ML; Henriques, AT; Klamt, F; Lerner, C; Moreira, JC; Mothes, B | 1 |
| Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T | 1 |
| Belenky, ML; Buchsbaum, DJ; Fiveash, JB; Gillespie, GY; Oliver, PG; Zhou, T | 1 |
| Brandsma, D; Bromberg, JE; de Bruin, HG; Smitt, PA; Swaak-Kragten, AT; Taal, W; van den Bent, MJ; van Es, CA | 1 |
| Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T | 1 |
| Chang, CH; Horton, J; Kramer, S; Nelson, JS; Perez-Tamayo, R; Salazer, O; Schoenfeld, D; Tsukada, Y; Weinstein, A | 1 |
| McVie, JG | 1 |
| Devineni, D; Gallo, JM; Klein-Szanto, A | 1 |
| Abe, H; Aida, T; Ikeda, J; Kaneko, S; Kashiwaba, T; Kawamoto, T; Mitsumori, K; Saitoh, H; Sawamura, Y | 1 |
| Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG | 1 |
| Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES | 1 |
| Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P | 1 |
| Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR | 1 |
| Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F | 1 |
| Fei, ZL; Gallo, JM; Klein-Szanto, A; Ma, J | 1 |
| Burton, E; Prados, M | 1 |
| Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D | 1 |
| Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Brock, CS; Evans, H; Matthews, J; Newlands, ES; O'Reilly, SM; Osman, S; Price, PM; Young, H | 1 |
| Cairncross, JG | 1 |
| Batchelor, T | 1 |
| Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J | 1 |
| Friedman, HS | 1 |
| Aravantinos, G; Christodoulou, C; Efstathiou, E; Janinis, J; Panopoulos, C; Samantas, E; Skarlos, D | 1 |
| Calvert, H; Friedman, HS; Kerby, T | 1 |
| Cher, L | 1 |
| Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH | 1 |
| Brandes, AA; Monfardini, S; Pasetto, LM; Vastola, F | 1 |
| Osoba, D | 1 |
| Ames, MM; Buckner, JC; Hatfield, AK; Johnson, PS; Krook, JE; Morton, RF; Nair, S; Novotny, PJ; Rajkumar, SV; Reid, JM; Safgren, SL; Scheithauer, BW | 1 |
| Bocangel, DB; Kokkinakis, DM; Moschel, RC; Pegg, AE; Schold, SC | 1 |
| Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R | 1 |
| Cave, C; Dinnes, J; Huang, S; Major, K; Milne, R | 1 |
| Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA | 1 |
| Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW | 1 |
| Macdonald, DR | 1 |
| Newlands, E; Stupp, R | 1 |
| Prados, M | 1 |
| Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C | 1 |
| Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ | 1 |
| Gander, M; Leyvraz, S; Newlands, E; Stupp, R | 1 |
| Dichgans, J; Rodemann, HP; Schulz, JB; Weller, M; Wick, A; Wick, W | 1 |
| Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K | 1 |
| Afra, D; Sipos, L; Vitanovics, D | 1 |
| Levin, VA; Wilson, CB | 1 |
| Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS | 1 |
| Brunat-Mentigny, M; Chastagner, P; Czorny, A; Lapras, C; Olive, D; Philip, T; Zucker, JM | 1 |
107 review(s) available for dacarbazine and Glioma
| Article | Year |
|---|---|
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Magnetic Iron Oxide Nanoparticles; O(6)-Methylguanine-DNA Methyltransferase; Peptides; RNA, Small Interfering; Temozolomide | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Temozolomide | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Middle Aged; Pancytopenia; Polymorphism, Single Nucleotide; Prognosis; Temozolomide; Tumor Suppressor Proteins | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glioma; Humans; Hydroxyurea; Lomustine; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Procarbazine; Randomized Controlled Trials as Topic; Temozolomide; Vincristine | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dosage Forms; Glioma; Humans; Neoplasm Recurrence, Local; Neurosurgical Procedures; Quality of Life; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Male; Middle Aged; Radiotherapy Dosage; Temozolomide | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Temozolomide | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wnt Signaling Pathway | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Electromagnetic Fields; Glioma; Humans; Mitosis; Neoplasm Recurrence, Local; Temozolomide | 2018 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Neoplasm Recurrence, Local; Radiation Injuries; Radiotherapy; Temozolomide | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Temozolomide | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted Therapy; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Grading; Particle Accelerators; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Grading; Temozolomide | 2014 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Death; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Glioma; Humans; Lomustine; Methylation; Multicenter Studies as Topic; Neoplasm Proteins; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Vincristine | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; Glioma; Humans; Temozolomide | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2014 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe; Glioma; Humans; Radiotherapy; Temozolomide; United States | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Isocitrate Dehydrogenase; Lomustine; Mutation; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Suppressor Proteins | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide; Treatment Outcome | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Temozolomide; Vincristine | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Disease-Free Survival; Eflornithine; Glioma; Humans; Mitolactol; Network Meta-Analysis; Nimustine; Probability; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide; Treatment Outcome; Vincristine | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioma; Humans; Mutation; Prognosis; Temozolomide; Treatment Outcome | 2016 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interactions; Glioma; Hematologic Diseases; Humans; Infections; Nausea; Temozolomide; Vomiting | 2006 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; ErbB Receptors; Gene Amplification; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Signal Transduction; Temozolomide; Up-Regulation | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioma; Humans; Medical Oncology; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Labeling; Glioblastoma; Glioma; Humans; Temozolomide | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma; Humans; Radionuclide Imaging; Temozolomide; Treatment Outcome | 2009 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Immunologic Factors; Lymphopenia; Melanoma; Temozolomide; Treatment Outcome | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Recurrence; Temozolomide; Treatment Outcome | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; Designer Drugs; DNA Methylation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; India; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Young Adult | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2010 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Silencing; Genetic Therapy; Glioma; Humans; Melanoma; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Genotype; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Temozolomide; Treatment Failure | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Neoplasm Grading; Temozolomide | 2011 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Staging; Temozolomide | 2011 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Temozolomide; Time Factors | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Risk Factors; Temozolomide; Young Adult | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Lomustine; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2012 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasm Grading; Pneumocystis carinii; Pneumonia, Pneumocystis; Risk Factors; Temozolomide | 2013 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Immunologic Factors; Temozolomide | 2012 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Glioma; Mice; Rats; Survival Analysis; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnosis, Differential; Ganglioglioma; Ganglioneuroma; Glioma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Papilledema; Paresis; Temozolomide; Treatment Outcome; Vision, Low | 2012 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Melanoma; Temozolomide | 2001 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Nitrosourea Compounds; Patient Selection; Survival Rate; Temozolomide | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Middle Aged; Survival Rate; Temozolomide; Vindesine | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Middle Aged; Radiotherapy; Radiotherapy Dosage; Survival Rate; Temozolomide | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Delivery Systems; Drug Implants; Glioma; Humans; Patient Selection; Prognosis; Temozolomide | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Glioma; Humans; Temozolomide | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Serine Endopeptidases; Temozolomide; Tetracyclines | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infant; Medulloblastoma; Temozolomide | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Glioma; Humans; Neurosurgical Procedures; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Procarbazine; Temozolomide | 2005 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Glioma; Humans; Lymphoma; Radiosurgery; Temozolomide | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Synergism; Genetic Therapy; Glioma; Humans; Interferon-beta; Nimustine; Radiotherapy; Temozolomide | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Glioma; Humans; Recurrence; Temozolomide | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgical Procedures; Radiotherapy; Temozolomide | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioma; Herpesviridae; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Temozolomide | 2006 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damage; DNA Methylation; DNA Mismatch Repair; DNA Repair; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Protein Kinases; Temozolomide; TOR Serine-Threonine Kinases | 2007 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Epilepsy; Forecasting; Genetic Markers; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Thromboembolism; Time Factors; Tomography, X-Ray Computed | 2006 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; DNA Damage; Drug Administration Schedule; Epilepsy; Forecasting; Glioblastoma; Glioma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Palliative Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Thrombophilia | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Nitroso Compounds; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Glioma; Humans; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Biological; Molecular Structure; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Temozolomide | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioma; Humans; Medical Oncology; Models, Biological; Neoplasm Metastasis; Oligodendroglioma; Signal Transduction; Temozolomide; Treatment Outcome | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioma; Humans; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Quality of Life; Temozolomide | 2007 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genes, Tumor Suppressor; Glioma; Humans; Loss of Heterozygosity; MicroRNAs; Molecular Diagnostic Techniques; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Radiation Tolerance; Radiotherapy; Temozolomide | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-Analysis as Topic; Oligodendroglioma; Randomized Controlled Trials as Topic; Temozolomide | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Delayed-Action Preparations; Glioma; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Temozolomide | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Gene Deletion; Glioma; Humans; Molecular Diagnostic Techniques; Neurosurgical Procedures; Pharmacogenetics; Reoperation; Temozolomide | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Magnetic Resonance Imaging; Necrosis; Neoplasm Recurrence, Local; Patient Selection; Radiation Injuries; Radiotherapy, Adjuvant; Risk Assessment; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A | 2008 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 1993 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Meningitis; Mice; Mice, Nude; Neoplasm Staging; Quality of Life; Temozolomide; Transplantation, Heterologous | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Incidence; Melanoma; Temozolomide | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; Temozolomide | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Glioma; Humans; Temozolomide | 2000 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Recurrence; Temozolomide; Treatment Outcome; United Kingdom | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life; Temozolomide | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Quality of Life; Temozolomide | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2001 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Lomustine; Medulloblastoma; Methotrexate; Nitrogen Mustard Compounds; Procarbazine; Semustine; Teniposide; Vincristine | 1975 |
142 trial(s) available for dacarbazine and Glioma
| Article | Year |
|---|---|
Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Interferon-alpha; Male; Middle Aged; Temozolomide; Young Adult | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oxides; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Glioma; Humans; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Systems; Female; Glioma; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Nanoparticles; Pilot Projects; Polymers; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Tumor Burden | 2018 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Temozolomide; Young Adult | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Semustine; Temozolomide | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Temozolomide | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Karnofsky Performance Status; Male; Quality of Life; Remission Induction; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2013 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Leukopenia; Male; Middle Aged; Nimustine; Postoperative Complications; Temozolomide; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; DNA, Neoplasm; Female; Glioma; Humans; Isocitrate Dehydrogenase; Lomustine; Male; Predictive Value of Tests; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2014 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy, Conformal; Research Design; Risk Factors; Temozolomide; Young Adult | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Radiotherapy, Conformal; Random Allocation; Survival Rate; Tamoxifen; Temozolomide; Thromboembolism; Treatment Outcome; Young Adult | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide; Young Adult | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Postoperative Period; Prognosis; Prospective Studies; Radiotherapy Dosage; Survival Rate; Temozolomide | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Temozolomide | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Treatment Outcome | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Temozolomide | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2015 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Lomustine; Male; Temozolomide; Young Adult | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quality of Life; Quinuclidines; Surveys and Questionnaires; Temozolomide | 2016 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Grading; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Young Adult | 2017 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life; Temozolomide | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Radiotherapy, Conformal; Temozolomide | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; Glioma; Humans; Immunotherapy; Male; Middle Aged; Temozolomide; Up-Regulation | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Dacarbazine; Female; Glioma; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Neuropsychological Tests; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2017 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Pons; Prognosis; Radiotherapy; Temozolomide; Tretinoin | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Procarbazine; Salvage Therapy; Survival Analysis; Temozolomide | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioma; Humans; Interferon-beta; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2008 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Guanine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioma; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotopes; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Temozolomide; Time Factors; Tyrosine; Young Adult | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Male; Pons; Prospective Studies; Temozolomide | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Delivery Systems; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2010 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Mutation; Procarbazine; Promoter Regions, Genetic; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine; Young Adult | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Double-Blind Method; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Japan; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Natural Killer T-Cells; Radiotherapy, Conformal; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Temozolomide; WT1 Proteins | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Pilot Projects; Temozolomide; Thrombocytopenia; Treatment Outcome | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Neoplasm Staging; Procarbazine; Proportional Hazards Models; Quality of Life; Recurrence; Risk Assessment; Risk Factors; Temozolomide; Time Factors; Treatment Outcome; United Kingdom; Vincristine | 2010 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Photosensitizing Agents; Radiotherapy; Temozolomide; Treatment Outcome | 2011 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Radiosurgery; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Interferon-beta; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Temozolomide | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Survival Rate; Tamoxifen; Temozolomide; Thrombocytopenia; Venous Thrombosis; Young Adult | 2012 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Diterpenes; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Prospective Studies; Retinaldehyde; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; North America; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Temozolomide; Vascular Endothelial Growth Factor A | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazine; Disease-Free Survival; Drug Combinations; Enzyme Inhibitors; Fatty Acids, Unsaturated; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Piperidines; Pyridines; Temozolomide; Vitamin E | 2011 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Temozolomide; Thallium Radioisotopes; Treatment Outcome; Young Adult | 2012 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Genetic Vectors; Glioma; Herpesvirus 1, Human; Humans; Immunotherapy; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Thymidine Kinase; Treatment Outcome; Valacyclovir; Valine | 2011 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioma; Guanine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Proportional Hazards Models; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide | 2012 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Leukopenia; Male; Middle Aged; Radiation Injuries; Radiotherapy, Conformal; Remission Induction; Survival Rate; Temozolomide; Young Adult | 2011 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Semustine; Temozolomide; Teniposide; Young Adult | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electronic Health Records; Glioma; Humans; Quality Assurance, Health Care; Radiotherapy Dosage; Temozolomide | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxides; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Female; Glioma; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Grading; Temozolomide; Treatment Outcome; Vorinostat | 2012 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Analysis; Temozolomide | 2014 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Multicenter Studies as Topic; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Temozolomide; Thrombocytopenia | 2002 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Temozolomide | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Etoposide; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isotretinoin; Male; Middle Aged; Neoplasm Recurrence, Local; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Procarbazine; Sleep Stages; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Seizures; Temozolomide; Treatment Outcome | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Quality of Life; Radiography; Seizures; Temozolomide; Treatment Outcome | 2003 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Proportional Hazards Models; Risk Assessment; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Temozolomide; Treatment Outcome; Water | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Temozolomide; Treatment Outcome | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Temozolomide | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Costs; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome | 2004 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Temozolomide | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Temozolomide; Time Factors | 2006 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Guanine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Outcome | 2006 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Hong Kong; Hospitals, Teaching; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide | 2005 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Time Factors; Treatment Outcome | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Quality of Life; Radiotherapy; Temozolomide; Time Factors; Treatment Outcome | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionine; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 Enzyme System; Dacarbazine; Disease-Free Survival; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Joint Diseases; Joints; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Risk Assessment; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Leukopenia; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome; Vomiting | 2006 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Survival Analysis; Temozolomide | 2007 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Leukopenia; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Temozolomide | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Female; Genetic Markers; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Protein p14ARF; Tumor Suppressor Proteins | 2006 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Monte Carlo Method; Radiobiology; Relative Biological Effectiveness; Temozolomide; Therapeutic Equivalency | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Glioma; Humans; Longitudinal Studies; Male; Middle Aged; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Survival Analysis; Survivors; Temozolomide; Time Factors; Treatment Outcome | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Prospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Drug Delivery Systems; Exotoxins; Female; Glioma; Humans; Infusions, Intralesional; Interleukin-13; Male; Middle Aged; Nervous System Diseases; Radiotherapy, Conformal; Recombinant Fusion Proteins; Temozolomide; Treatment Outcome | 2007 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Male; Middle Aged; Prognosis; Temozolomide | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Monoterpenes; Neoplasm Recurrence, Local; Oncogene Protein p21(ras); Signal Transduction; Survival Rate; Temozolomide; Transforming Growth Factor beta; Treatment Outcome | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Mas; Pyrimidines; Temozolomide | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Survival Analysis; Temozolomide | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Glioma; Humans; Lomustine; Maximum Tolerated Dose; Temozolomide | 2008 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Prednisone; Probability; Prognosis; Radiotherapy Dosage; Random Allocation; Semustine | 1983 |
Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Child; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Nimustine; Radiation Dosage; Supratentorial Neoplasms; Treatment Outcome; Vincristine | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 1996 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Temozolomide | 1997 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chromatography, High Pressure Liquid; Dacarbazine; Drug Administration Schedule; England; Female; Glioma; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome | 1999 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Radiopharmaceuticals; Temozolomide; Tomography, Emission-Computed | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Recurrence; Temozolomide | 2000 |
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2000 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Temozolomide | 2001 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Stomach Neoplasms; Temozolomide | 1992 |
680 other study(ies) available for dacarbazine and Glioma
| Article | Year |
|---|---|
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dog Diseases; Dogs; Glioma; Humans; Temozolomide; Tumor Suppressor Proteins | 2021 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Humans; Temozolomide | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cathelicidins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Mitochondria; Neoplasm Recurrence, Local; Nerve Growth Factor; Temozolomide | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Diseases; Lymphopenia; Methylhydrazines; Neutropenia; Temozolomide; Thrombocytopenia | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retrospective Studies; Temozolomide | 2022 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolomide; Tumor Microenvironment | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Proteomics; Tandem Mass Spectrometry; Temozolomide | 2023 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Hydrogels; Temozolomide | 2020 |
Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Glioma; Humans; Retrospective Studies; Syndrome | 2021 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gas Chromatography-Mass Spectrometry; Glioma; Humans; Mice; Mice, Inbred C57BL; O(6)-Methylguanine-DNA Methyltransferase; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2020 |
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology).
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Italy; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glioma; Humans; Male; Methadone; Middle Aged; Patient Safety; Proportional Hazards Models; Retrospective Studies; Risk; Surveys and Questionnaires; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Female; Glioma; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Management; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Neuroepithelial; Neurosurgical Procedures; Oligodendroglioma; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Rate; Temozolomide | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Cattle; Cell Line, Tumor; Coumaric Acids; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Mice; Models, Molecular; Mustard Plant; Nanoparticles; Phosphorylcholine; Polymethacrylic Acids; Rats; Serum Albumin, Bovine; Temozolomide; Tissue Distribution | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Rats; RNA, Messenger; Temozolomide | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC Class I; Glioma; Humans; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Signal Transduction; Stem Cells; Temozolomide | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Glioma; Humans; Reactive Oxygen Species; Temozolomide; Thiazolidines | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; Drug Resistance, Neoplasm; Female; Genotype; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Prognosis; Temozolomide; Vomiting | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Repositioning; Drug Synergism; Glioma; Humans; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Neoplastic Stem Cells; Oligodendroglia; Quetiapine Fumarate; Temozolomide; Tumor Burden | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Mice, Nude; Temozolomide | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; GTP-Binding Proteins; Humans; Mesenchymal Stem Cells; Neoplastic Stem Cells; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Stem Cells; Temozolomide; Transglutaminases; Tretinoin; Up-Regulation | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplasm Invasiveness; Temozolomide; Tumor Suppressor Proteins | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Multidrug Resistance-Associated Proteins; Mutation; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Synergism; Epithelial-Mesenchymal Transition; Glioma; Hedgehog Proteins; Humans; Signal Transduction; Temozolomide; Translocation, Genetic; Zinc Finger Protein GLI1 | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line, Tumor; Cell Proliferation; Chlorpromazine; Dacarbazine; Dopamine Antagonists; Drug Repositioning; Drug Resistance, Neoplasm; Electron Transport Complex IV; Glioma; Humans; Mice, Nude; Mitochondria, Heart; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Glioma; Humans; Hypoxia; Mitochondria; Neoplastic Stem Cells; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cyclohexenes; Dacarbazine; DNA Damage; Doxorubicin; Fibroblasts; Glioma; Humans; Oxidation-Reduction; Sesquiterpenes; Temozolomide | 2018 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Guanosine; Humans; Membrane Potential, Mitochondrial; Receptors, Purinergic P1; Temozolomide | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Temozolomide | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Ethnicity; Female; Glioma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Germany; Glioma; Hematologic Neoplasms; Humans; Incidence; Infant; Kaplan-Meier Estimate; Male; Switzerland; Temozolomide | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioma; Hydrogels; Male; Nanocomposites; Nanoparticles; Paclitaxel; Rats; Rats, Wistar; Temozolomide; Temperature | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Connexin 43; Dacarbazine; Glioma; Green Fluorescent Proteins; Humans; Neoplasm Proteins; Temozolomide; Transfection | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhibitors; Female; Glioma; Humans; Isocitrate Dehydrogenase; Mice; Mice, SCID; Mutation; NAD; Nicotinamide Phosphoribosyltransferase; Piperidines; Random Allocation; Stress, Physiological; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dog Diseases; Dogs; Female; Glioma; Male; Radiosurgery; Survival Analysis; Temozolomide | 2018 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Dacarbazine; Female; Glioma; Humans; Immunotherapy, Adoptive; Lymphopenia; Male; Middle Aged; Prospective Studies; T-Lymphocyte Subsets; Temozolomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Glioma; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Mice; Neoplastic Stem Cells; Protein Transport; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Signal Transduction; Survival Rate; Temozolomide; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Glioma; Humans; Inflammation; Macrophages; Mice; Receptors, Purinergic; Temozolomide; Tumor Microenvironment | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mitochondria; Sodium-Hydrogen Exchangers; Temozolomide; Ultrasonic Waves | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Sex Factors; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2017 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Shape; Dacarbazine; Glioma; Humans; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2018 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomide | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Ventricles; Dacarbazine; Disease Models, Animal; Doublecortin Domain Proteins; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hyaluronan Receptors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microtubule-Associated Proteins; Mutation; Nestin; Neurofibromin 1; Neuropeptides; Proto-Oncogene Proteins c-sis; PTEN Phosphohydrolase; RNA, Small Interfering; Temozolomide | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Glioma; Humans; Hydrogels; Mice; Neoplasm Recurrence, Local; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Time Factors; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioma; Humans; MicroRNAs; Neoplasm Invasiveness; Nuclear Proteins; Phenotype; Protein-Tyrosine Kinases; Temozolomide | 2017 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Cohort Studies; Dacarbazine; Etoposide; Female; Glioma; Humans; Ifosfamide; Leukopenia; Male; Neoplasm Grading; Prospective Studies; Temozolomide; Treatment Outcome; Vincristine | 2018 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioma; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins c-sis; Temozolomide; Vascular Endothelial Growth Factor A | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; ErbB Receptors; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Hyperthermia, Induced; Rats, Wistar; Reference Standards; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Temperature | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Proton Therapy; Retrospective Studies; Temozolomide; Young Adult | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Propyl Gallate; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Ganglioglioma; Glioblastoma; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plant Extracts; Plant Leaves; Temozolomide; Zinc Oxide | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Dacarbazine; Female; Glioma; Humans; Male; Neoplasm Grading; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tumor Burden | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Dacarbazine; Dendrimers; Drug Liberation; Drug Stability; Glioma; Half-Life; Humans; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Particle Size; Rats; Rats, Wistar; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Temozolomide; Tissue Distribution | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Monocytes; Temozolomide; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Female; Glioma; Humans; Ligands; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Temozolomide; Tumor Cells, Cultured | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazine; Temozolomide | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Oligodendroglioma; Temozolomide | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Down-Regulation; F-Box-WD Repeat-Containing Protein 7; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Prognosis; Receptor, Notch1; RNA, Small Interfering; Temozolomide; Ubiquitin-Protein Ligases | 2018 |
NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Male; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Stem Cells; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Tumor Burden | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isocitrate Dehydrogenase; MicroRNAs; Mutation; Oncogenes; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide; Up-Regulation | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Dacarbazine; Datasets as Topic; Disease-Free Survival; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Prognosis; Temozolomide; TWEAK Receptor | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replication; DNA-Binding Proteins; DNA, Mitochondrial; Gene Expression Regulation, Neoplastic; Glioma; Humans; Melatonin; Membrane Potential, Mitochondrial; Mitochondrial Proteins; Molecular Targeted Therapy; Neoplasm Proteins; Reactive Oxygen Species; RNA, Messenger; Temozolomide; Transcription Factors; Transcription, Genetic | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Signal Transduction; SOX9 Transcription Factor; Temozolomide | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glycogen Synthase Kinase 3 beta; Humans; Models, Molecular; Muscle Proteins; Phosphorylation; Protein Domains; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Glioma; Humans; Male; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Temozolomide; Tumor Burden | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Radiosurgery; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Memory; Middle Aged; Temozolomide; Treatment Outcome | 2018 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Heterografts; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2018 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Delivery Systems; Folic Acid; Gene Silencing; Genes, bcl-2; Glioma; Humans; Micelles; Nanoparticles; Particle Size; Polyethylene Glycols; Polyethyleneimine; Polymers; Proton Magnetic Resonance Spectroscopy; Rats; RNA, Messenger; RNA, Small Interfering; Static Electricity; Temozolomide | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Genotype; Glioma; Humans; Infant; Kaplan-Meier Estimate; Life Style; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Temozolomide; Young Adult | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; Glioma; Humans; Occupational Exposure; Temozolomide | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Electron Transport Complex III; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mice, Nude; Middle Aged; Mitochondrial Proteins; Prognosis; RNA Interference; RNA, Small Interfering; Temozolomide | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Neoplasm Transplantation; Neoplastic Stem Cells; Nerve Tissue Proteins; Radiotherapy; Rats; Rats, Sprague-Dawley; Receptors, Nerve Growth Factor; Temozolomide; Up-Regulation | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Dacarbazine; DNA Fragmentation; Drugs, Chinese Herbal; Fas Ligand Protein; Glioma; Humans; Lignans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2018 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Procollagen-Proline Dioxygenase; Protein Disulfide-Isomerases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Temozolomide | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Temozolomide; Tumor Burden; World Health Organization; Young Adult | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA, Neoplasm; Glioma; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Pyrroles; Sunitinib; Temozolomide; Tumor Cells, Cultured; Vascular Resistance | 2013 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide; Tumor Suppressor Proteins | 2012 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Microglia; NAD; Oxidative Stress; Pentosyltransferases; Quinolinic Acid; Temozolomide; Tryptophan; Tryptophan Oxygenase | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Humans; Immunohistochemistry; Luciferases; Mice; Mice, Nude; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Oligonucleotides; Paraffin Embedding; Plasmids; Real-Time Polymerase Chain Reaction; Temozolomide | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analysis; Dacarbazine; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Glioma; Humans; Interleukin-1 Receptor-Associated Kinases; NF-kappa B; Proteome; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Temozolomide; Toll-Like Receptors | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Glioma; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MicroRNAs; Mutant Proteins; Neoplasm Proteins; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Transfection; Tumor Cells, Cultured | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Dacarbazine; Drug Synergism; Extracellular Fluid; Glioma; Humans; Male; Microdialysis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Female; Germ Cells; Glioma; Humans; Male; Pregnancy; Proteins; RNA, Long Noncoding; Spermatogenesis; Spermatozoa; Temozolomide; Tumor Suppressor Proteins | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ceramides; Clone Cells; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Glucosyltransferases; Humans; Meperidine; Radiation, Ionizing; Signal Transduction; Sphingomyelin Phosphodiesterase; Temozolomide; Treatment Outcome | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connexin 43; Cytochromes c; Dacarbazine; Dose-Response Relationship, Drug; Fluoresceins; Glioma; Humans; Mitochondria; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Temozolomide; Time Factors; Transfection | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Mutation; Receptor-Like Protein Tyrosine Phosphatases, Class 2; Signal Transduction; Temozolomide | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclobutanes; Dacarbazine; Feasibility Studies; Glioma; Magnetic Resonance Imaging; Male; Methionine; Permeability; Rats; Temozolomide; Treatment Outcome | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell Survival; Dacarbazine; Disease Progression; Extracellular Matrix; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Glioma; Humans; Integrin alphaV; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Oligopeptides; Proteomics; Reproducibility of Results; RNA, Messenger; Spheroids, Cellular; Survival Analysis; Temozolomide | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase; Glioma; Humans; Plasma Gases; Temozolomide; Tumor Stem Cell Assay | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Female; Glioma; Humans; Spinal Neoplasms; Temozolomide; Treatment Outcome | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired Infections; Dacarbazine; Female; Glioma; Hematologic Diseases; Humans; Logistic Models; Male; Middle Aged; Neutropenia; Predictive Value of Tests; Temozolomide; Thrombocytopenia | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy, Adoptive; Injections, Intralesional; Mice; Mice, Inbred C57BL; Temozolomide | 2013 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neurosurgical Procedures; Photosensitizing Agents; Retrospective Studies; Surgery, Computer-Assisted; Temozolomide; Treatment Outcome | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric Compounds; Glioma; Humans; Magnetic Resonance Imaging; Mice; Nanoparticles; Polymers; Radiography; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Glioma; Heavy Ion Radiotherapy; Humans; Infant; Neoplasm Grading; Photons; Retrospective Studies; Temozolomide | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; Comet Assay; Cyclin-Dependent Kinases; Dacarbazine; Drug Synergism; Female; Flavonoids; Fluorescent Antibody Technique; Glioma; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Leupeptins; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell Cycle; Cells, Cultured; Dacarbazine; Dietary Supplements; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Triacetin | 2014 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Paclitaxel; Temozolomide | 2014 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioma; Humans; Lipogenesis; Mice; Molecular Chaperones; Neoplasm Grading; Prognosis; RNA, Messenger; Signal Transduction; Temozolomide; Transcription Factors; Transcription, Genetic; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Mice; Neoplastic Stem Cells; Oncolytic Viruses; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Clone Cells; Connexin 43; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; HEK293 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Molecular Sequence Data; Protein Binding; Rats; RNA, Messenger; Temozolomide | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Temozolomide | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Glioma; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Subcutaneous Tissue; Temozolomide; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality Therapy; Dacarbazine; Ganciclovir; Genes, Transgenic, Suicide; Genes, Viral; Genetic Therapy; Genetic Vectors; Glioma; Herpesvirus 1, Human; Humans; Male; Neoplasms, Experimental; Rats; Temozolomide; Thymidine Kinase; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; RNA Interference; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Glioma; Humans; Matrix Metalloproteinase 14; Mice; MicroRNAs; Radiation; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Follow-Up Studies; Glioma; Humans; Laminin; Male; Rats; Rats, Nude; Survival Analysis; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Cortex; Cognition Disorders; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Leukoencephalopathies; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Temozolomide; Young Adult | 2014 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Elongation Factor 2 Kinase; Glioma; Humans; Male; Mice; Protein Kinase Inhibitors; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Temozolomide | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutational Analysis; Glioma; Humans; Mutagenesis; Neoplasm Grading; Neoplasm Recurrence, Local; Nuclear Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Protein p53; X-linked Nuclear Protein | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Disease Models, Animal; Glioma; Male; Pertussis Toxin; Rats; Rats, Wistar; Survival Rate; Temozolomide | 2014 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Immunotherapy; Magnetic Resonance Imaging; Neoplasm Grading; Neoplasms; Precision Medicine; Remission Induction; Temozolomide; Translational Research, Biomedical | 2013 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chemoradiotherapy; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Radiation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; ErbB Receptors; Glioma; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Neoplasm Grading; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; RNA Interference; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Transfection; Tumor Suppressor Proteins | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Glioma; Humans; Male; Pons; Retrospective Studies; Survival Analysis; Temozolomide | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Endothelial Cells; Enediynes; Glioma; Heterografts; Humans; Male; Mice, Nude; Neovascularization, Pathologic; Rats; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; Glioma; Humans; Male; MAP Kinase Signaling System; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Middle Aged; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays; Young Adult | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Gene Expression; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mice; Mice, Nude; Mutation; Temozolomide | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Metabolome; Mutation; Temozolomide | 2014 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Olfaction Disorders; Oxidative Stress; Radiotherapy; Saliva; Salivary Proteins and Peptides; Taste Disorders; Temozolomide | 2015 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Radiotherapy, Conformal; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Female; Fibrin Tissue Adhesive; Glioma; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Temozolomide | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; CTLA-4 Antigen; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Knockout; T-Lymphocytes, Regulatory; Temozolomide | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Disease Models, Animal; Diterpenes; Drug Synergism; Epoxy Compounds; Glioma; Humans; Mice; Neoplasm Transplantation; NF-kappa B; Phenanthrenes; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stimulation, Chemical; Temozolomide; Transcription, Genetic; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relationship, Drug; Fatal Outcome; Glioma; Humans; Male; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Retrospective Studies; Switzerland; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Autophagy; Autophagy-Related Protein-1 Homolog; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Microtubule-Associated Proteins; Morpholines; Protein Serine-Threonine Kinases; Pyrones; Signal Transduction; Temozolomide | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; Cell Death; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Dipeptides; Glioma; Humans; Macrolides; Neoplasm Proteins; Pentacyclic Triterpenes; Temozolomide; Triterpenes | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioma; Humans; Temozolomide | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enediynes; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Rats; Signal Transduction; Temozolomide | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Magnetic Resonance Imaging; Neoplasm Transplantation; Rats; Rats, Wistar; Temozolomide | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes, ras; Glioma; Humans; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neovascularization, Pathologic; ras Proteins; Signal Transduction; Temozolomide | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Telomerase; Temozolomide | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Genes, ras; Genes, Tumor Suppressor; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Signal Transduction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Carcinogenesis; Cell Line, Tumor; Cell Movement; Child; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Transforming Growth Factor beta; Young Adult | 2014 |
NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Mice, Nude; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems; Glioma; Half-Life; Humans; Lactic Acid; Madin Darby Canine Kidney Cells; Male; Nanoparticles; Polyesters; Polyethylene Glycols; Polymers; Polysorbates; Rats; Rats, Wistar; Temozolomide; Tissue Distribution | 2016 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Glioma; Homologous Recombination; Humans; Isocitrate Dehydrogenase; Mutation; Rad51 Recombinase; Temozolomide | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Tumor Burden | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Hematologic Diseases; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Republic of Korea; Retrospective Studies; Severity of Illness Index; Sex Factors; Temozolomide; Vomiting; Young Adult | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydrocarbons, Brominated; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred BALB C; MicroRNAs; Sesquiterpenes; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Endpoint Determination; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Seizures; Survival Analysis; Temozolomide | 2015 |
Are we done with dose-intense temozolomide in recurrent glioblastoma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Glioma; Humans; Neoplasm Grading; Temozolomide | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding Sites; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioma; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MicroRNAs; Response Elements; RNA Interference; RNA-Binding Proteins; Temozolomide; Transcription, Genetic; Transcriptional Activation | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Glioma; Humans; Insulin-Like Growth Factor Binding Protein 2; Integrin beta1; MAP Kinase Signaling System; Neoplasm Invasiveness; Temozolomide; Tissue Array Analysis | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Imidazoles; Mice; O(6)-Methylguanine-DNA Methyltransferase; ras Proteins; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Glioma; Mice; Neoplasm Transplantation; Peptides; Temozolomide; Trans-Activators | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; HEK293 Cells; Humans; Introns; Male; Middle Aged; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, RNA; Temozolomide; Translocation, Genetic; Young Adult | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality Therapy; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Optic Nerve Glioma; Radiosurgery; Temozolomide; Vision Disorders; Visual Fields | 2015 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Heat-Shock Proteins; HSC70 Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Molecular Chaperones; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2015 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Glioma; Humans; Isoenzymes; Neoplastic Stem Cells; Rats; Retinal Dehydrogenase; RNA, Messenger; Temozolomide | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizures; Temozolomide | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Oncogene Proteins; R-SNARE Proteins; Temozolomide | 2015 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Photochemotherapy; Photosensitizing Agents; Porphyrins; Temozolomide; Treatment Outcome | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Membrane Proteins; MicroRNAs; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; RNA, Small Interfering; Temozolomide; Transfection | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Follow-Up Studies; Glioma; Humans; Image Interpretation, Computer-Assisted; Middle Aged; Multivariate Analysis; Neoplasm Grading; Principal Component Analysis; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2014 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Reactive Oxygen Species; Temozolomide | 2015 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide; Time Factors | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Deubiquitinating Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoenzyme Techniques; Membrane Proteins; Neoplasm Grading; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2014 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Estrogen Receptor beta; Flavanones; Glioma; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspase 3; Cell Proliferation; Dacarbazine; Flow Cytometry; Glioma; Humans; Inhibitor of Apoptosis Proteins; Proteolysis; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Mice, Nude; Temozolomide; Tumor Suppressor Protein p53 | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Female; Glioma; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Prognosis; Repressor Proteins; RNA, Small Interfering; Temozolomide; Transcription Factors; Treatment Outcome; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2014 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; NF-kappa B; Osteopontin; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Temozolomide | 2015 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; Glioma; Hematoporphyrins; Male; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Wistar; Temozolomide; Treatment Outcome | 2014 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Hospitals, Religious; Hospitals, University; Humans; Male; Neoplasm Grading; Neurons; Prognosis; Prospective Studies; Rome; Survival Analysis; Temozolomide | 2015 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Male; Mice; Microbubbles; Survival Analysis; Temozolomide; Tight Junctions; Tumor Burden; Ultrasonics; Xenograft Model Antitumor Assays | 2014 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogenic Effect, Viral; Dacarbazine; Gene Expression; Genes, Transgenic, Suicide; Genetic Vectors; Glioma; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Spheroids, Cellular; Temozolomide; Transduction, Genetic; Tumor Cells, Cultured; Virus Replication; Y-Box-Binding Protein 1 | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; E2F3 Transcription Factor; Gene Knockdown Techniques; Glioma; Humans; MicroRNAs; Molecular Sequence Data; RNA Interference; Temozolomide | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarbazine; Drug Synergism; Glioma; Humans; Mitochondria; Rats; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electron Transport Complex I; Glioma; Humans; Male; Methylation; Mitochondria; Promoter Regions, Genetic; Rats, Sprague-Dawley; Tamoxifen; Temozolomide; Tumor Suppressor Proteins | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cellular Senescence; Chemoradiotherapy; Cyclin B1; Dacarbazine; Glioma; Humans; Immunohistochemistry; Male; Mice, Nude; Mitosis; Polyploidy; Receptors, Erythropoietin; RNA Interference; RNAi Therapeutics; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compounds; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Models, Molecular; Muscle Proteins; Nitrophenols; Peptide Fragments; Piperazines; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Temozolomide; Tumor Cells, Cultured | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Coculture Techniques; Connexin 43; Dacarbazine; Drug Resistance, Neoplasm; Gap Junctions; Gene Knockdown Techniques; Glioma; Humans; Temozolomide; Tumor Microenvironment; Vincristine | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Gene Deletion; Genetic Predisposition to Disease; Glioma; Humans; Male; Middle Aged; Missouri; Prevalence; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; MutL Protein Homolog 1; Nuclear Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrones; RNA Interference; RNA, Small Interfering; Temozolomide | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Peduncle; Child; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infratentorial Neoplasms; Irinotecan; Laser Therapy; Male; Neoplasms, Multiple Primary; Neurofibromatosis 1; Neuroimaging; Optic Nerve Glioma; Supratentorial Neoplasms; Temozolomide | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Glioma; Humans; Neoplasm Grading; RNA Interference; Temozolomide; Tetraspanins; Up-Regulation | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kaplan-Meier Estimate; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; PTEN Phosphohydrolase; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Glioma; Heme Oxygenase-1; Humans; Imidazoles; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Temozolomide | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Dacarbazine; DNA Damage; Enzyme Activation; Glioma; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phenotype; Protein Serine-Threonine Kinases; Single-Cell Analysis; Sirolimus; Temozolomide; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA Repair-Deficiency Disorders; Female; Glioma; Humans; Male; Mutation; Receptors, Immunologic; Statistics, Nonparametric; Temozolomide; Tumor Suppressor Proteins | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolomide; Up-Regulation | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Genome, Human; Glioma; Humans; Isoenzymes; Mice; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Temozolomide; Transcription, Genetic | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Genes, p53; Glioma; Humans; Inhibitor of Apoptosis Proteins; Mutation; PTEN Phosphohydrolase; Silybin; Silymarin; Survivin; Temozolomide | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm Recurrence, Local; Neurosurgical Procedures; Nuclear Proteins; Prognosis; Temozolomide; Tumor Suppressor Protein p53; X-linked Nuclear Protein | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Differentiation Protein 2; RNA Interference; Temozolomide | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Male; Mice, Nude; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins; Receptors, Tumor Necrosis Factor, Member 10c; Temozolomide; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor Decoy Receptors; Xenograft Model Antitumor Assays | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor; Dacarbazine; Drug Evaluation, Preclinical; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luminescent Proteins; Mice; Mice, Nude; Optical Imaging; Temozolomide | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dopamine; Gene Expression; Glioma; Macrophages; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Temozolomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Frontal Lobe; Glioma; Hippocampus; Humans; Neoplasm Recurrence, Local; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Supratentorial Neoplasms; Temozolomide; Tumor Burden; Young Adult | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carboplatin; Child; Child, Preschool; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Induction Chemotherapy; Infant; Kaplan-Meier Estimate; Male; Pilot Projects; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Proportional Hazards Models; Radiation Tolerance; Radiotherapy; Rats; RNA, Small Interfering; Temozolomide; Thrombospondins; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Lomustine; Neoplasm Grading; Neoplasm Staging; Oligodendroglioma; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Lomustine; Neoplasm Grading; Neoplasm Staging; Oligodendroglioma; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investigational; Tissue Distribution | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Male; Middle Aged; Nitrosourea Compounds; Prospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Odds Ratio; Radiotherapy Dosage; Regression Analysis; Sex Factors; Temozolomide; Young Adult | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Carmustine; Dacarbazine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Inhibitory Concentration 50; Oxidative Stress; Rats; Temozolomide | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition; Glioma; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Snails; Temozolomide; Twist-Related Protein 1 | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Glioblastoma; Glioma; Histones; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Mice; Potassium Channel Blockers; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Signal Transduction; Temozolomide | 2015 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; Protein Kinase Inhibitors; src-Family Kinases; Temozolomide | 2016 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Light; Molecular Structure; Photochemical Processes; Photosensitizing Agents; Porphyrins; Rats; Temozolomide; Tumor Stem Cell Assay | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells; Endothelin Receptor Antagonists; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Pyrimidines; Sulfonamides; Temozolomide | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Phenotype; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells; Proto-Oncogene Proteins c-cbl; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2015 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Temozolomide; Transfection; Up-Regulation | 2014 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Mice; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glioma; Humans; Imidazoles; Inhibitory Concentration 50; Male; Mice, SCID; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioma; Humans; Male; MAP Kinase Kinase 2; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Grading; Prognosis; Temozolomide; Treatment Outcome; Up-Regulation | 2016 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; Male; Mice; Rabbits; Solubility; Temozolomide; Tissue Distribution | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastoma; Glioma; Lipids; Mice; Nanostructures; Phosphatidylethanolamines; Polyethylene Glycols; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanostructures; Particle Size; Temozolomide; Vincristine | 2016 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma; Humans; Models, Biological; Molecular Targeted Therapy; Neoplastic Stem Cells; Temozolomide | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; DNA Methylation; Epigenesis, Genetic; Glioma; HeLa Cells; Humans; Oxidative Stress; Rats; Temozolomide | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon Type I; Male; Mice; Neoplastic Stem Cells; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice, Nude; RNA Interference; RNAi Therapeutics; Temozolomide; Time Factors; Transfection; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice, Inbred C57BL; MicroRNAs; Promoter Regions, Genetic; Temozolomide | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Nausea; Prospective Studies; Temozolomide; Vomiting; Young Adult | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Combinations; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Nanoparticles; Peptide Nucleic Acids; Peptides; Porosity; Rats; Silicon Dioxide; Temozolomide | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Glucose; Humans; Paclitaxel; Temozolomide | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanotechnology; Temozolomide | 2015 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioma; Humans; Rats; Survival Analysis; Temozolomide | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Seizures; Temozolomide; Treatment Outcome | 2016 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanoparticles; PTEN Phosphohydrolase; Temozolomide | 2015 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Positron-Emission Tomography; ROC Curve; Seizures; Sensitivity and Specificity; Temozolomide; Young Adult | 2016 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioma; Humans; Protein Interaction Maps; Signal Transduction; Survival Analysis; Temozolomide | 2015 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Physicians; Surveys and Questionnaires; Temozolomide | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Prognosis; Repressor Proteins; Temozolomide | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Gene Knockdown Techniques; Glioma; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; RNA, Messenger; Survival Analysis; Temozolomide; Treatment Outcome; Tryptophan; Tumor Burden | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Movement; Cell Proliferation; Chromosomal Proteins, Non-Histone; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Middle Aged; Neoplasm Grading; Nuclear Proteins; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Trans-Activators; Tumor Cells, Cultured | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Green Fluorescent Proteins; Humans; Mice, Transgenic; Microglia; Microscopy, Confocal; Microscopy, Fluorescence; Neovascularization, Pathologic; Organ Culture Techniques; Rats, Wistar; Reproducibility of Results; Temozolomide; Tumor Microenvironment | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mesenchymal Stem Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Dacarbazine; Early Diagnosis; Female; Follow-Up Studies; Glioma; Humans; Leukoencephalopathies; Male; Prospective Studies; Radiotherapy; Temozolomide | 2015 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Peptide Nucleic Acids; Phenotype; Surface Plasmon Resonance; Temozolomide | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloride Channels; Comet Assay; Dacarbazine; Flow Cytometry; Glioma; Humans; Nitrobenzoates; Patch-Clamp Techniques; Temozolomide | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regulation; Gene Transfer Techniques; Genetic Therapy; Glioma; Green Fluorescent Proteins; Magnetic Resonance Imaging; Male; Nanoparticles; Open Reading Frames; Plasmids; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Survival Rate; Temozolomide; Transferrin | 2016 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Temozolomide; Transfection | 2015 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysfunction; Cranial Irradiation; Dacarbazine; Delirium; Dexamethasone; Diagnosis, Differential; Encephalitis, Herpes Simplex; Female; Glioma; Herpesvirus 1, Human; Humans; Leukocytosis; Magnetic Resonance Imaging; Seizures; Temozolomide; Young Adult | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mutation; Signal Transduction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioma; Humans; Liposomes; Phosphatidylethanolamines; Polyethylene Glycols; Quercetin; Random Allocation; Rats; Rats, Sprague-Dawley; Temozolomide | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioma; Immunotherapy; Inflammation; Lipids; Mice, Inbred C57BL; Nanotubes, Carbon; Neoplasm Invasiveness; Oligodeoxyribonucleotides; Polyethylene Glycols; Spleen; Temozolomide; Treatment Outcome | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Nude; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Sirolimus; SOX9 Transcription Factor; SOXB1 Transcription Factors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Reproducibility of Results; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; HeLa Cells; Humans; Plasma Gases; Reactive Oxygen Species; Temozolomide | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Chromosomal Proteins, Non-Histone; Dacarbazine; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kinesins; Male; MicroRNAs; Neoplasm Grading; Oncogene Proteins; Temozolomide | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Multivariate Analysis; Mutation, Missense; Neoplasm Grading; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Temozolomide | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Nanoparticles; Oxidation-Reduction; Particle Size; Porosity; Reducing Agents; Silicon Dioxide; Temozolomide | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Brain Edema; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Magnetic Resonance Imaging; Rats, Wistar; Sulfasalazine; Temozolomide; Tumor Microenvironment | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Kruppel-Like Transcription Factors; Mice; Real-Time Polymerase Chain Reaction; Repressor Proteins; RNA Interference; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neoplasm Proteins; RNA, Small Interfering; Signal Transduction; Temozolomide; Transfection | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Drug Therapy, Combination; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Microglia; Neoplasms, Experimental; Neoplastic Stem Cells; Phosphorylation; Primary Cell Culture; Pyrazoles; Temozolomide | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Ionomycin; Large-Conductance Calcium-Activated Potassium Channels; Membrane Potentials; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Histones; Humans; Infant; Male; Radiotherapy; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neoplasms, Neuroepithelial; Temozolomide | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Glioma; Humans; MAP Kinase Signaling System; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioma; Humans; Immunohistochemistry; Male; NIMA-Related Kinase 1; Temozolomide; Tumor Stem Cell Assay; Up-Regulation | 2016 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy; Temozolomide | 2017 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Endoplasmic Reticulum Stress; Fluoxetine; Glioma; Membrane Potential, Mitochondrial; Rats; Signal Transduction; Temozolomide; Transcription Factor CHOP | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Gastrins; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Purines; Radioisotopes; Signal Transduction; Temozolomide | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; NF-E2-Related Factor 2; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Large-Conductance Calcium-Activated Potassium Channels; Microfilament Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Mice; MicroRNAs; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Sp1 Transcription Factor; Temozolomide; Treatment Outcome | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioma; Hippocampus; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; S100 Proteins; Statistics, Nonparametric; Temozolomide; Young Adult | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioma; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Wnt Proteins | 2016 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Enzyme Activation; Gene Knockdown Techniques; Glioma; GTPase-Activating Proteins; Humans; Lysosomes; Membrane Fusion; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide | 2017 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA-Activated Protein Kinase; Drug Synergism; Female; Glioma; Humans; Mice; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Models, Theoretical; Nitrophenols; Piperazines; Signal Transduction; Sulfonamides; Systems Biology; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Glioma; Humans; Imidazoles; Pyrimidinones; Signal Transduction; Temozolomide; Tetraspanins; TOR Serine-Threonine Kinases | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Systems, Clinical; DNA Repair; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Glioma; High-Throughput Nucleotide Sequencing; Histone Deacetylase Inhibitors; Histones; Humans; RNA; RNA, Small Interfering; Temozolomide; Transcription, Genetic; Treatment Outcome; Valproic Acid | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotaxis; Cyclic GMP-Dependent Protein Kinase Type I; Dacarbazine; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurons; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Stem Cells; Temozolomide | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; China; Combined Modality Therapy; Contraindications; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Young Adult | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Progression; Embryonic Stem Cells; Glioma; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Octamer Transcription Factor-3; Prognosis; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; Cell Death; Cellular Senescence; Dacarbazine; Glioma; Homologous Recombination; Humans; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combined Modality Therapy; Dacarbazine; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Therapy; Glioma; Humans; Lentivirus; Neoplasm Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Phosphatase 2C; Temozolomide | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Temozolomide | 2016 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Glioma; Humans; Temozolomide | 2017 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptides; Drug Synergism; Glioma; Humans; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide; Vimentin | 2016 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Temozolomide | 2017 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Fibrinogen; Gelatin; Glioma; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogels; Models, Biological; Neoplastic Stem Cells; Porosity; Printing, Three-Dimensional; Temozolomide; Tissue Scaffolds; Vascular Endothelial Growth Factor A | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mice; Neoplasm Invasiveness; Phosphotransferases (Alcohol Group Acceptor); Rats; Spheroids, Cellular; Temozolomide; Time-Lapse Imaging; Tumor Cells, Cultured | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Deferiprone; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Inhibitory Concentration 50; Iron Chelating Agents; Pyridones; Temozolomide | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kaplan-Meier Estimate; Male; Membrane Glycoproteins; Microarray Analysis; Middle Aged; Neoplasm Grading; Prognosis; Temozolomide | 2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Temozolomide; Treatment Outcome | 2016 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Dynamin III; Exosomes; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Temozolomide; Transcription Factor RelA | 2017 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Gene Expression; Glioma; Homeodomain Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene Expression; Glioma; Humans; MAP Kinase Signaling System; Phenotype; Phosphorylation; Rats; Temozolomide; Vascular Endothelial Growth Factor C | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioma; Humans; Kaplan-Meier Estimate; MicroRNAs; NF-kappa B; Phenotype; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Tolerance; RNA Interference; Temozolomide; Time Factors; Transcription, Genetic; Transfection | 2016 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioma; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Temozolomide; Valproic Acid; Young Adult | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Metal Nanoparticles; Silver Compounds; Temozolomide | 2017 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin-Like Growth Factor I; Membrane Potential, Mitochondrial; MicroRNAs; Reactive Oxygen Species; Signal Transduction; Survival Rate; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Glioma; Humans; Nuclear Proteins; Pyridines; Pyrimidines; Receptor, Notch1; Signal Transduction; Temozolomide; Tumor Suppressor Proteins; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2016 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Temozolomide; Young Adult | 2017 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Longitudinal Studies; Male; Models, Theoretical; Procarbazine; Temozolomide; Vincristine | 2017 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Drug Synergism; Female; Glioma; Humans; Mice; Neoplasm Transplantation; Protein Binding; Receptor, TIE-2; Ribonuclease, Pancreatic; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2016 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Dacarbazine; gamma-Glutamylcyclotransferase; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Space; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 8; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Receptor, Notch3; RNA, Messenger; Signal Transduction; Temozolomide | 2017 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glutathione; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Rats; Sulfasalazine; Temozolomide | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; In Vitro Techniques; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Binding; PTEN Phosphohydrolase; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; Temozolomide; Tumor Suppressor Proteins | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; Glioma; Humans; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Temozolomide | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Guanine; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Replication Protein C; Temozolomide; Thiostrepton | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Temozolomide | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Models, Biological; Neoplasm Grading; Temozolomide | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Glioblastoma; Glioma; Glycogen Synthase Kinase 3; Humans; In Situ Nick-End Labeling; Phosphorylation; Phytotherapy; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sesquiterpenes; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glioma; Humans; Nanofibers; Neoplasm Recurrence, Local; Rats, Wistar; Survival Analysis; Temozolomide; Theranostic Nanomedicine | 2017 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance Imaging; Models, Theoretical; Neoplasm Grading; Temozolomide | 2016 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Temozolomide; Treatment Outcome | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2008 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Female; Glioma; Health Status Indicators; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Temozolomide; Treatment Outcome | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Female; Glioblastoma; Glioma; Hepatocytes; Humans; Lomustine; Male; Membrane Glycoproteins; Middle Aged; Procarbazine; Recombinant Fusion Proteins; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vincristine | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; ErbB Receptors; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Nude; Mice, SCID; PTEN Phosphohydrolase; Radiation Tolerance; Stem Cells; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioma; Male; Rats; Rats, Sprague-Dawley; Temozolomide; Tetrahydroisoquinolines; Tissue Culture Techniques; Xenograft Model Antitumor Assays | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioblastoma; Glioma; Humans; Temozolomide | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Procarbazine; Prognosis; Radiotherapy; Radiotherapy Dosage; Temozolomide; Vincristine | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy Dosage; Temozolomide; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Lymphoma, Non-Hodgkin; Mice; Middle Aged; Neoplasms, Second Primary; Risk Assessment; Temozolomide | 2008 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Survival; Cycloheximide; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Stability; Gene Expression Regulation, Neoplastic; Glioma; Green Fluorescent Proteins; Guanine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Protein Synthesis Inhibitors; Recombinant Fusion Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2009 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarbazine; Female; Glioma; Humans; Temozolomide | 2009 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Paclitaxel; RNA, Small Interfering; Telomerase; Temozolomide | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Mice; Mice, Nude; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interactions; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intermediate Filament Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Nerve Tissue Proteins; Nestin; RNA-Binding Proteins; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nimustine; Temozolomide | 2009 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Genetic Vectors; Glioma; Humans; Microscopy, Fluorescence; Signal Transduction; Stem Cell Transplantation; Stem Cells; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Combined Modality Therapy; Dacarbazine; Erythropoietin; Glioma; Gliosarcoma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Survival Analysis; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Reoperation; Survival Analysis; Survivors; Temozolomide; Time Factors | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Senescence; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Dacarbazine; DNA Methylation; Glioma; Heterochromatin; Histones; Humans; Methyl-CpG-Binding Protein 2; Temozolomide | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Glioma; Humans; Isotope Labeling; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tissue Distribution | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Radiation; Glioma; Humans; Kaplan-Meier Estimate; Middle Aged; Radiation Dosage; Radiotherapy; Retrospective Studies; Temozolomide; Young Adult | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Diagnostic Errors; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Magnetic Resonance Imaging; Male; Mice; Microscopy, Fluorescence; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Temozolomide; Treatment Outcome | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioma; Glutathione S-Transferase pi; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Neoplasm Staging; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Risk Factors; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Glioma; Humans; PTEN Phosphohydrolase; Pyrimidines; Temozolomide; Thiazoles | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, Tumor; Cell Survival; Cyclosporine; Cytostatic Agents; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioma; Humans; Indazoles; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pentacyclic Triterpenes; Polymerase Chain Reaction; Retinoids; Temozolomide; Triterpenes | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DNA, Viral; Female; Glioma; Humans; Middle Aged; Opportunistic Infections; Temozolomide; Tomography, X-Ray Computed | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Flow Cytometry; Forkhead Transcription Factors; Glioma; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Rats; Rats, Inbred F344; Spleen; T-Lymphocytes, Regulatory; Temozolomide; Tumor Cells, Cultured | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; DNA Methylation; Etoposide; Female; Glioma; Humans; Interferon-beta; Magnetic Resonance Imaging; Male; Nitrosourea Compounds; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Dacarbazine; Glioma; Humans; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Temozolomide | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Cells, Cultured; Chromones; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Humans; Mice; Mice, Nude; Mitoxantrone; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Temozolomide | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Administration Schedule; Drug Monitoring; Glioma; Humans; Lymphopenia; Nausea; Netherlands; Neutropenia; Nurse Practitioners; Nurse's Role; Nursing Evaluation Research; Oncology Nursing; Prospective Studies; Statistics, Nonparametric; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Mitosis; Oncolytic Virotherapy; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell Line, Tumor; Corpus Striatum; Dacarbazine; Drug Evaluation, Preclinical; Glioma; Indomethacin; Injections, Intraperitoneal; Male; Nanocapsules; Neovascularization, Pathologic; Random Allocation; Rats; Rats, Wistar; Supratentorial Neoplasms; Temozolomide; Tumor Burden | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Time; Treatment Outcome | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Drug Implants; Glioma; Humans; Maximum Tolerated Dose; Mice; Polymers; Rats; Rats, Wistar; Temozolomide; Tissue Distribution; Tumor Cells, Cultured | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Genetic Therapy; Genetic Vectors; Glioma; Humans; Interleukins; Mice; Mice, Nude; Oncolytic Virotherapy; Promoter Regions, Genetic; Recombinant Proteins; Temozolomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Prognosis; Research; Temozolomide | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Temozolomide; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding Factors, Epidemiologic; Dacarbazine; Female; Glioma; Humans; Hypersensitivity; Immunoglobulin E; Immunotherapy; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; San Francisco; Surveys and Questionnaires; Temozolomide | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Temozolomide | 2010 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Folic Acid Antagonists; Glioma; Humans; Melanoma; Molecular Structure; Poly(ADP-ribose) Polymerases; Pyrimethamine; Temozolomide | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dietary Supplements; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Modification Methylases; DNA Repair Enzymes; Folic Acid; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Platelet-Derived Growth Factor; Protein Binding; Proto-Oncogene Proteins c-sis; Repetitive Sequences, Nucleic Acid; Sp1 Transcription Factor; Sp3 Transcription Factor; Survival Analysis; Survivin; Temozolomide; Tumor Suppressor Proteins | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidase; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; G2 Phase; Glioma; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; In Situ Nick-End Labeling; Membrane Proteins; Middle Aged; Prognosis; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Humans; Temozolomide; Thalidomide | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioma; Humans; Interferon-beta; Temozolomide | 2009 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Diagnostic Imaging; Disease Models, Animal; Glioma; Humans; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Luciferases; Luminescent Agents; Male; Neoplasm Transplantation; Rats; Rats, Nude; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2010 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azacitidine; Brain Neoplasms; Cell Line, Tumor; CpG Islands; Dacarbazine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide; Young Adult | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neoplasms; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fluorometry; Glioma; Glutathione; Humans; Medulloblastoma; Methionine; Methotrexate; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Female; Flow Cytometry; Glioma; Humans; Immunoblotting; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Mice; Mice, Nude; Rats; Rats, Nude; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Temozolomide; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Kinetics; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Oligodendroglioma; Retrospective Studies; Temozolomide; Young Adult | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; Dendritic Cells; Disease Models, Animal; Drug Therapy, Combination; Female; Glioma; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Survival Analysis; T-Lymphocytes, Regulatory; Temozolomide | 2010 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Lomustine; Procarbazine; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine | 2009 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Recurrence; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportunistic Infections; Temozolomide | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide; Tumor Suppressor Proteins | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Therapy, Combination; Female; Glioma; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Genetic Therapy; Glioma; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Time Factors; Transfection | 2010 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Doxorubicin; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Vincristine | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Temozolomide; Treatment Outcome | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Chemokine CXCL12; Dacarbazine; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioma; Humans; Pyrrolidinones; Receptors, CXCR; Temozolomide | 2010 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End Labeling; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Temozolomide | 2011 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Rats; Staining and Labeling; Temozolomide | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Profiling; Glioma; Humans; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Response Relationship, Drug; Fatal Outcome; Glioma; Humans; Male; Recurrence; Temozolomide; Thrombocytopenia | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Knockdown Techniques; Glioma; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Female; France; Glioma; Humans; Male; Middle Aged; Polyesters; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nitrosourea Compounds; Retrospective Studies; Temozolomide; Treatment Outcome | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Models, Biological; Mutation; Octreotide; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Time Factors; Transfection | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Embryonic Stem Cells; Enzyme-Linked Immunosorbent Assay; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glioma; Humans; Immunoenzyme Techniques; Interleukins; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Transgenes; Tumor Stem Cell Assay | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Follow-Up Studies; Genetic Markers; Glioma; Humans; Incidence; Loss of Heterozygosity; Neoplasm Staging; Prognosis; Radiotherapy; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Temozolomide; Treatment Outcome | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Glioma; Gossypol; Humans; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Signal Transduction; Temozolomide; Transfection; Tumor Suppressor Proteins | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioma; Humans; Microsatellite Instability; Microsatellite Repeats; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide | 2010 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioma; Humans; Mutation; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Spectroscopy; Male; Middle Aged; Necrosis; Radiation Injuries; Radiotherapy; Retrospective Studies; Temozolomide; Young Adult | 2010 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2011 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Division; Cell Line, Tumor; Dacarbazine; Flow Cytometry; Glioblastoma; Glioma; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; Immune Tolerance; Immunity, Humoral; Immunity, Innate; Immunoglobulin E; Lipopolysaccharide Receptors; Male; Middle Aged; Receptors, IgE; Temozolomide; Young Adult | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Predictive Value of Tests; Radiotherapy, Adjuvant; Severity of Illness Index; Statistics, Nonparametric; Temozolomide | 2010 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Glioma; Humans; Lactic Acid; Male; Neovascularization, Pathologic; Phthalazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyridines; Rats; Rats, Sprague-Dawley; Temozolomide; Treatment Outcome | 2010 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioma; Humans; Kaplan-Meier Estimate; Loss of Heterozygosity; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Glioma; Hedgehog Proteins; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Neoplastic Stem Cells; Radiation Tolerance; RNA, Small Interfering; Temozolomide; Transcription Factors; Transcription, Genetic; Up-Regulation; Zinc Finger Protein GLI1 | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Probability; Prospective Studies; Retrospective Studies; Temozolomide; Time Factors; Young Adult | 2011 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA, Mitochondrial; Drug Resistance, Neoplasm; Electron Transport Chain Complex Proteins; Glioma; Humans; Mice; Mitochondria; Neoplasm Proteins; Neoplasm Transplantation; Oxygen Consumption; Temozolomide; Transplantation, Heterologous | 2010 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dacarbazine; Female; Glioma; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Myeloproliferative Disorders; NAD(P)H Dehydrogenase (Quinone); Neoplasms, Neuroepithelial; O(6)-Methylguanine-DNA Methyltransferase; Patients; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Temozolomide | 2011 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Female; Glioma; Humans; Isocitrate Dehydrogenase; Loss of Heterozygosity; Male; Middle Aged; Mutation; Pharmacogenetics; Predictive Value of Tests; Retrospective Studies; Statistics as Topic; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retreatment; Retrospective Studies; Survival Analysis; Temozolomide; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; Glioma; Humans; Infertility, Female; Oocytes; Pregnancy; Pregnancy Outcome; Reproductive Techniques, Assisted; Retrospective Studies; Temozolomide | 2010 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Neurosurgical Procedures; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dacarbazine; Glioma; Humans; Meloxicam; Temozolomide; Thiazines; Thiazoles; Time Factors; Tumor Cells, Cultured; X-Rays | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CCL2; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Glioma; Humans; Immunotherapy, Active; Macrophages; Mice; Mice, Inbred C57BL; Mice, SCID; Myeloid Cells; Neoplasm Transplantation; Poly I-C; Statistics, Nonparametric; Temozolomide | 2011 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Excipients; Glioma; Humans; Microscopy, Electron, Scanning; Particle Size; Polypropylenes; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Platelet Count; Prospective Studies; Sensitivity and Specificity; Temozolomide; Thrombocytopenia; Young Adult | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Glioma; Hemochromatosis Protein; Histocompatibility Antigens Class I; HSP72 Heat-Shock Proteins; Humans; Membrane Proteins; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Tumor Suppressor Proteins | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Seizures; Temozolomide; Treatment Outcome | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Mice; Neoplasm Transplantation; Piperidines; Prenylation; Pyridines; Radiation, Ionizing; ras Proteins; Signal Transduction; Temozolomide; Time Factors | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infant; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Hospitals; Humans; Incidence; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; PrPC Proteins; Receptors, Thrombin; RNA, Small Interfering; Temozolomide; Transfection | 2012 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell Line, Tumor; Cells, Cultured; Cytological Techniques; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Glioma; Heat-Shock Proteins; Humans; Immunohistochemistry; Mice; Rats; Temozolomide | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; Humans; Oxidation-Reduction; Temozolomide; Valproic Acid | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; Glioma; Glycoproteins; Humans; Immunoenzyme Techniques; Peptides; Rad51 Recombinase; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; X-Rays | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; RNA, Messenger; Temozolomide; Treatment Outcome | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Synergism; Glioma; Guanine; Humans; Hydroxylamines; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasing Hormone; Dacarbazine; Dexamethasone; Glioma; Humans; Male; Mice; Mice, Nude; Rats; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Mice; Receptors, CXCR; Temozolomide | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, Regulator; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xeroderma Pigmentosum Group D Protein; Young Adult | 2011 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Evaluation, Preclinical; Enzyme Activation; Glioma; Glutathione S-Transferase pi; Growth Inhibitors; Humans; Nitric Oxide Donors; para-Aminobenzoates; Rats; Rats, Nude; Temozolomide | 2012 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Incidence; Logistic Models; Male; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Time Factors | 2011 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Radiosurgery; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Dacarbazine; ErbB Receptors; Glioma; Humans; Immunoblotting; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; X-Rays | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Child; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Infusions, Intravenous; Male; Nausea; Neutropenia; Nimustine; Temozolomide; Teniposide; Thrombocytopenia; Young Adult | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prospective Studies; Protons; Temozolomide; Treatment Outcome | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioma; Humans; PTEN Phosphohydrolase; Radiation Tolerance; Radiation, Ionizing; Temozolomide; Tumor Cells, Cultured | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinomatosis; Temozolomide | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, Western; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Daunorubicin; Genetic Therapy; Genetic Vectors; Glioma; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Oncolytic Virotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Virus Replication; Y-Box-Binding Protein 1 | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Glioma; Humans; Imidazoles; O(6)-Methylguanine-DNA Methyltransferase; Pilot Projects; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Temozolomide | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Gamma Rays; Glioma; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Oligopeptides; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2011 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Injections, Intravenous; Male; Temozolomide; Young Adult | 2012 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte Count; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Hospitalization; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Outcome Assessment, Health Care; Prospective Studies; Temozolomide; Time Factors | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2011 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neuropsychological Tests; Neurosurgical Procedures; Quality of Life; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Drug Administration Schedule; Etoposide; Female; Glioma; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Retrospective Studies; Temozolomide; Treatment Failure | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Enzyme Induction; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; Male; Oligonucleotide Array Sequence Analysis; Temozolomide | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Dacarbazine; Dendritic Cells; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Ipilimumab; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2012 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Drug Resistance, Neoplasm; Electron Transport Complex IV; Glioma; Glutathione; Glutathione Disulfide; Humans; Reactive Oxygen Species; Temozolomide | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell Line, Tumor; Dacarbazine; Docosahexaenoic Acids; Down-Regulation; gamma-Linolenic Acid; Glioblastoma; Glioma; Humans; MicroRNAs; Neoplasm Proteins; Osmolar Concentration; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Up-Regulation | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; ErbB Receptors; Glioma; Humans; rho-Associated Kinases; RNA, Small Interfering; Temozolomide; Transfection | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Neoplasm Recurrence, Local; Retreatment; Temozolomide | 2011 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Etoposide; Female; Glioblastoma; Glioma; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Supratentorial Neoplasms; Temozolomide | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gamma Rays; Glioma; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Valproic Acid | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cytochromes c; Dacarbazine; Down-Regulation; Gene Knockdown Techniques; Glioma; Humans; MicroRNAs; Mitochondria; Proto-Oncogene Proteins; RNA, Small Interfering; Signal Transduction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromones; Dacarbazine; Down-Regulation; Drug Synergism; Glioma; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Reactive Oxygen Species; Resveratrol; Stilbenes; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Time Factors | 2011 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islands; Dacarbazine; DNA Methylation; Down-Regulation; Female; Gene Knockdown Techniques; Gene Silencing; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Oligodendroglia; Peroxiredoxins; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Young Adult | 2012 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Temozolomide | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Dacarbazine; Electric Impedance; Female; Gene Knockout Techniques; Glioblastoma; Glioma; Humans; Immunohistochemistry; Male; Microtubule-Associated Proteins; Middle Aged; Neurofilament Proteins; Phosphopyruvate Hydratase; Real-Time Polymerase Chain Reaction; Temozolomide; Tubulin; Young Adult | 2011 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Longitudinal Studies; Male; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapatite; Glioma; Humans; Integrin alphaVbeta3; Lactic Acid; Microspheres; Nanostructures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Temozolomide | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarbazine; Glioma; Rats; Receptors, CXCR; Receptors, CXCR4; Temozolomide; Transcription, Genetic | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Survival Analysis; Temozolomide; Temperature; Tumor Suppressor Proteins | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Glutamic Acid; Humans; Male; Mice; Mice, Nude; Oxaloacetic Acid; Rats; Rats, Sprague-Dawley; Temozolomide; Tumor Burden | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Utilization; Female; France; Glioma; Guideline Adherence; Humans; Male; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Temozolomide | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Ions; Male; Meningioma; Middle Aged; Proton Therapy; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Temozolomide; Young Adult | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Humans; Osteonectin; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Temozolomide | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Contrast Media; Dacarbazine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Glioma; Kinetics; Lactic Acid; Light; Magnetic Resonance Imaging; Magnetite Nanoparticles; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanomedicine; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polysorbates; Rats; Scattering, Radiation; Solubility; Spectrophotometry, Atomic; Technology, Pharmaceutical; Temozolomide | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Brain Neoplasms; Calpain; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Selenium; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; Haemophilus influenzae; Humans; Immunocompromised Host; Japan; Male; Middle Aged; Pneumocystis carinii; Pneumonia; Pneumothorax; Pseudomonas aeruginosa; Radiography; Staphylococcus aureus; Temozolomide | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Risk Factors; Temozolomide; Time Factors; Treatment Failure | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Male; MAP Kinase Signaling System; Membrane Lipids; Mice; Mice, Nude; Microscopy, Confocal; Oleic Acids; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; ras Proteins; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Interactions; Extracellular Fluid; Glioma; Humans; Male; Metabolic Clearance Rate; Microdialysis; Rats; Rats, Nude; Temozolomide; Time Factors | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus Cinguli; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Regression Analysis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Glioma; Hyperbaric Oxygenation; Rats; Rats, Wistar; Temozolomide | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Arachnoid; Bevacizumab; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Young Adult | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Temozolomide; Tumor Suppressor Proteins; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Flow Cytometry; Glioma; Humans; Immunoblotting; rho GTP-Binding Proteins; Signal Transduction; Temozolomide | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Mitochondria; Reactive Oxygen Species; Temozolomide | 2012 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Bevacizumab; Biopsy; Cerebral Angiography; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Hydrocephalus; Hypothalamic Neoplasms; Intracranial Arteriovenous Malformations; Middle Aged; Paresis; Radiosurgery; Subarachnoid Hemorrhage; Temozolomide; Tomography, X-Ray Computed | 2013 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Glioma; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Necrosis; Paclitaxel; Polyglutamic Acid; Temozolomide | 2012 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Fluorescent Antibody Technique; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; Humans; Immunoenzyme Techniques; Mice; Mice, SCID; Neoplastic Stem Cells; Peptides; Receptors, CXCR4; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dacarbazine; Delayed-Action Preparations; Female; Glioma; Humans; Mice; Mice, Nude; Microspheres; Random Allocation; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Inhibitory Concentration 50; Male; Microscopy, Confocal; Middle Aged; Neoplastic Stem Cells; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dendrimers; Drug Synergism; Genetic Therapy; Glioma; Humans; MicroRNAs; Nanoparticles; PTEN Phosphohydrolase; STAT3 Transcription Factor; Temozolomide | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Fibronectins; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Peptide Fragments; Temozolomide; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Glioma; Humans; Hyperbaric Oxygenation; Temozolomide; Vascular Endothelial Growth Factor A | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Mice; Monoterpenes; Nelfinavir; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dacarbazine; Female; Glioma; Humans; Inflammation; Male; Middle Aged; Neovascularization, Pathologic; Temozolomide | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Decitabine; Down-Regulation; Epigenesis, Genetic; Gene Silencing; Glioma; Humans; Methylation; MicroRNAs; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Fasting; Glioblastoma; Glioma; Insulin-Like Growth Factor I; Luminescence; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Rats; Temozolomide | 2012 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Disease Management; Glioma; Humans; Male; Middle Aged; Steroids; Temozolomide; Treatment Outcome | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Glioma; Humans; Hypersensitivity, Delayed; Immune Tolerance; Skin Tests; Temozolomide | 2012 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephalitis, Herpes Simplex; Glioma; Humans; Magnetic Resonance Imaging; Male; Recurrence; Temozolomide; Virus Activation | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Electromagnetic Radiation; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutant Proteins; Mutation; Radiation Tolerance; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarbazine; Down-Regulation; Flow Cytometry; Fluorescent Antibody Technique; Glioma; Humans; Microscopy, Electron, Transmission; NF-E2-Related Factor 2; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiosurgery; Retrospective Studies; Temozolomide | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Implants; Feasibility Studies; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Postoperative Complications; Prospective Studies; Supratentorial Neoplasms; Survival Analysis; Survival Rate; Temozolomide | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Female; Gels; Glioma; Humans; Neoplasm Transplantation; Paclitaxel; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide | 2013 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Synergism; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microspheres; Random Allocation; Temozolomide; Transcriptional Activation; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Magnetic Resonance Imaging; Male; Necrosis; Neoplasm Recurrence, Local; Nervous System Diseases; Temozolomide | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Pons; Prognosis; Survival Rate; Temozolomide | 2013 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; Histone Deacetylase Inhibitors; Humans; Temozolomide; Valproic Acid | 2012 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Craniotomy; Cytoplasm; Dacarbazine; Diagnostic Imaging; Glioma; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Red Fluorescent Protein; Temozolomide | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Dacarbazine; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Green Fluorescent Proteins; GTPase-Activating Proteins; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Time Factors; Transfection | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioma; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Semen; Sperm Motility; Temozolomide; Time Factors | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Oncogene Protein v-akt; Signal Transduction; src-Family Kinases; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2014 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dacarbazine; DNA Damage; DNA Mismatch Repair; DNA Modification Methylases; DNA-Binding Proteins; Glioma; Guanine; Homologous Recombination; Humans; Protein Serine-Threonine Kinases; Temozolomide; Tumor Suppressor Proteins | 2013 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Nucleus; Cytosol; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Temozolomide; Thioguanine; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; DNA Repair; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; G2 Phase; Glioblastoma; Glioma; Humans; Mitosis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dacarbazine; DNA Fragmentation; Drug Resistance, Neoplasm; Glioma; Humans; In Situ Nick-End Labeling; Neoplasm Invasiveness; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; Drug Interactions; Glioma; Indoles; Neoplasm Transplantation; Neoplasms, Experimental; Pyrroles; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Tumor Cells, Cultured | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Ependymoma; Female; Glioblastoma; Glioma; Humans; Image Enhancement; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Oligodendroglioma; Paclitaxel; Procarbazine; Sensitivity and Specificity; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony-Forming Units Assay; Dacarbazine; G2 Phase; Glioma; Guanine; Humans; Mitosis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Tumor Cells, Cultured | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Ribonucleotide Reductases; Temozolomide; Tumor Cells, Cultured | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Glioma; Humans; Male; Retrospective Studies; Survival Rate; Temozolomide | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; Carbon Radioisotopes; Dacarbazine; Glioma; Humans; Male; Middle Aged; Temozolomide; Tomography, Emission-Computed | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Infant; Male; Retrospective Studies; Temozolomide | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression; Glioma; Guanine; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Temozolomide; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Glioma; Humans; Radiation Injuries; Reproducibility of Results; Temozolomide | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hematopoiesis; Humans; Models, Biological; Neutrophils; Temozolomide | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Neoplasm Staging; Prognosis; Temozolomide | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2003 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Macrolides; Microtubule-Associated Proteins; Organelles; Temozolomide | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kinetics; Male; Middle Aged; Temozolomide; Treatment Outcome | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistance, Neoplasm; G2 Phase; Glioma; Humans; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinases; Temozolomide; Tumor Cells, Cultured | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Methylation; DNA Repair; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cisplatin; Dacarbazine; Doxorubicin; Drug Interactions; Glioma; Humans; Temozolomide; Topotecan; Tumor Cells, Cultured | 2004 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioma; Humans; Temozolomide; Up-Regulation | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Temozolomide | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Drug Interactions; Glioma; Humans; Temozolomide; Thiazoles; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dacarbazine; DNA Damage; Drug Interactions; Drug Resistance, Neoplasm; Glioma; Humans; Immunotherapy, Active; Intramolecular Oxidoreductases; T-Lymphocytes, Cytotoxic; Temozolomide; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylcellulose Sodium; Combined Modality Therapy; Contrast Media; Dacarbazine; Dose Fractionation, Radiation; Female; Gadolinium DTPA; Glioma; Humans; Interferon Inducers; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Poly I-C; Polylysine; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Humans; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Phosphorus Isotopes; Temozolomide | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Temozolomide | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2005 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Etoposide; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase; G2 Phase; Glioma; Humans; Mice; Mice, Transgenic; Phosphorylcholine; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Protein p53 | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Glioma; Gliosarcoma; Humans; Male; Methionine; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Positron-Emission Tomography; Prospective Studies; Statistics, Nonparametric; Stereotaxic Techniques; Temozolomide; Tomography, Emission-Computed, Single-Photon | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 9; Cytogenetics; Dacarbazine; Female; Gene Deletion; Genetic Markers; Glioblastoma; Glioma; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Models, Genetic; Multivariate Analysis; Nucleic Acid Hybridization; Paraffin; Prognosis; Proportional Hazards Models; Sex Factors; Temozolomide; Time Factors; Treatment Outcome | 2005 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioma; Humans; In Situ Nick-End Labeling; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Temozolomide; Thalidomide; Transplantation, Heterologous | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Dacarbazine; Glioma; Immunohistochemistry; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Temozolomide | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Infections; Lymphopenia; Male; Middle Aged; Temozolomide | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Synergism; Drug Therapy, Combination; Glioma; Male; Microcirculation; Radiosurgery; Rats; Rats, Sprague-Dawley; Temozolomide; Thalidomide | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dacarbazine; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Perilipin-3; Pregnancy Proteins; Proteomics; rhoA GTP-Binding Protein; Temozolomide; Vesicular Transport Proteins | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Glioma; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinases; Temozolomide | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosum; Dacarbazine; Frontal Lobe; Glioma; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Postoperative Care; Temozolomide | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neuronal; Dacarbazine; Disease Models, Animal; Glioma; Hippocampus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Pyridines; Rats; Rats, Inbred F344; Rats, Wistar; Temozolomide; Tumor Cells, Cultured | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Temozolomide | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioma; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Temozolomide; Tissue Inhibitor of Metalloproteinase-2; Up-Regulation | 2006 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cycle; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Damage; Fas Ligand Protein; Fas-Associated Death Domain Protein; Flow Cytometry; Glioma; Guanine; Humans; Methylnitronitrosoguanidine; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2007 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Dacarbazine; Gamma Rays; Glioma; Hematopoietic Stem Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Signal Transduction; Temozolomide; Transcription, Genetic; Transforming Growth Factor beta | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Glioma; Glucose; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Temozolomide; Treatment Outcome | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Glioma; Humans; Lymphopenia; Temozolomide | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Damage; Etoposide; Glioma; Humans; Membrane Proteins; Oxidation-Reduction; Phosphorylation; Temozolomide | 2007 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Lomustine; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Glioma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; Temozolomide | 2006 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rats; Temozolomide | 2007 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Medical Oncology; Neurology; Societies, Medical; Spain; Temozolomide; Treatment Outcome | 2006 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Comet Assay; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide; Tumor Suppressor Protein p53 | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2007 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Glioma; Humans; Interferon-beta; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide | 2006 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Temozolomide; Thrombocytopenia; Treatment Outcome | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Male; Middle Aged; Nausea; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Remission Induction; Temozolomide; Young Adult | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Male; Radiotherapy Dosage; Survival Rate; Temozolomide | 2006 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group F Protein; Fanconi Anemia Complementation Group Proteins; Glioma; Guanine; Humans; Protein Processing, Post-Translational; RNA Interference; RNA, Small Interfering; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins; Ubiquitins | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Delayed-Action Preparations; Drug Implants; Drug Screening Assays, Antitumor; Glioma; Maximum Tolerated Dose; Polymers; Rats; Rats, Inbred F344; Temozolomide | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line; Cell Proliferation; Cell Survival; Dacarbazine; Drug Evaluation, Preclinical; Endothelial Cells; Glioma; Humans; Hydrogen-Ion Concentration; Hypoxia-Inducible Factor 1, alpha Subunit; Microdialysis; Neoplasm Transplantation; Rats; Rats, Nude; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2007 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Incidence; Lymphoma; Magnetic Resonance Imaging; Microarray Analysis; Neuronavigation; Patient Care Team; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Radiotherapy, Conformal; Temozolomide | 2006 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine; Diagnosis, Differential; Female; Glioma; Humans; Laryngeal Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Positron-Emission Tomography; Radiotherapy; Temozolomide | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured | 2007 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genes, p53; Glioma; Humans; Mice; Mice, Nude; Oncolytic Virotherapy; Simplexvirus; Temozolomide; Tumor Suppressor Proteins | 2006 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazine; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Genes, p53; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Biology; Temozolomide | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic Resonance Imaging; Mice; Mice, Mutant Strains; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retroviridae; Temozolomide | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Genotype; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL22; Chemokines; Chemotaxis, Leukocyte; Cytoplasm; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma; Humans; Receptors, CCR2; Receptors, CCR4; T-Lymphocytes, Regulatory; Temozolomide | 2008 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Mice; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Suppressor Proteins; Valproic Acid | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; Glioma; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oncolytic Virotherapy; Sirolimus; Temozolomide | 2007 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Down-Regulation; Eye Neoplasms; Female; Genes, Reporter; Glioma; Humans; Interferon Type I; Luciferases; Mice; Mice, Inbred BALB C; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2008 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Survival; Dacarbazine; Flow Cytometry; Giant Cells; Glioma; Humans; Mutation; Protein Serine-Threonine Kinases; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of Health Care; Glioma; Humans; Temozolomide; United Kingdom | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte Count; Dacarbazine; Glioma; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Risk Assessment; Risk Factors; Temozolomide | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Female; Glioma; Immunity, Cellular; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neoplasm Proteins; Recombinant Fusion Proteins; Repressor Proteins; Spleen; Survival Analysis; Survivin; tat Gene Products, Human Immunodeficiency Virus; Temozolomide; Transduction, Genetic; Treatment Outcome | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Dosage; Gene Expression; Glioblastoma; Glioma; Humans; Immunohistochemistry; Molecular Sequence Data; Netherlands; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Tumor Suppressor Proteins | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Radiotherapy Dosage; Relative Biological Effectiveness; Temozolomide; Therapeutic Equivalency; Tumor Burden | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Genetic Therapy; Glioma; Humans; Mice; Oligonucleotides, Antisense; Oligoribonucleotides; RNA; RNA, Long Noncoding; RNA, Untranslated; Telomerase; Temozolomide | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; White People | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA, Complementary; Female; Gene Transfer Techniques; Genetic Therapy; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Temozolomide | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA Repair; Gene Silencing; Glioma; Humans; Immunohistochemistry; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Transplantation, Heterologous | 2007 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Genetic Markers; Glioma; Humans; Lymphoma; Prognosis; Promoter Regions, Genetic; Temozolomide; Topotecan; Tumor Suppressor Proteins | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Galectin 1; Glioma; Humans; Mice; RNA, Small Interfering; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Collagen Type IV; Dacarbazine; Drug Combinations; Glioma; Immunoenzyme Techniques; Indoles; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid; Cryptococcus neoformans; Dacarbazine; Dexamethasone; Fatal Outcome; Fluconazole; Flucytosine; Glioma; Humans; Immunosuppression Therapy; Lomustine; Male; Meningitis, Cryptococcal; Opportunistic Infections; Temozolomide; Treatment Outcome | 2008 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacarbazine; Drug Synergism; Edaravone; Free Radical Scavengers; Glioma; Rats; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazine; Embryo, Nonmammalian; Embryonic Development; Feasibility Studies; Glioma; Green Fluorescent Proteins; Humans; Luminescent Proteins; Radiation-Sensitizing Agents; Red Fluorescent Protein; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2008 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Genes, myc; Glioma; Humans; In Situ Hybridization, Fluorescence; Medulloblastoma; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neuroectodermal Tumors, Primitive; Prognosis; Proto-Oncogene Proteins; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell Line, Transformed; Cell Line, Tumor; Complex Mixtures; Dacarbazine; Glioma; Humans; Porifera; Temozolomide | 2009 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Mice; Mice, Nude; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome | 2008 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexanes; Dacarbazine; Factor VIII; Glioma; Microscopy, Confocal; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Rats; Sesquiterpenes; Temozolomide; Tumor Cells, Cultured | 1996 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Feasibility Studies; Female; Fluorouracil; Glioma; Humans; Middle Aged; Spectrum Analysis; Temozolomide; Tomography, Emission-Computed | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, Antisense; Endothelial Growth Factors; Genetic Vectors; Glioma; Humans; Lymphokines; Male; Neoplasm Proteins; Neovascularization, Pathologic; Rats; Rats, Nude; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Glioma; Humans; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide; United States | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indwelling; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Male; Neoplasm Transplantation; Rats; Rats, Nude; Temozolomide; Time Factors; Tumor Cells, Cultured | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Glioma; Humans; Quality of Life; Temozolomide | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Gene Transfer Techniques; Glioma; Humans; Inhibitory Concentration 50; Sensitivity and Specificity; Temozolomide; Transcription Factors; Tumor Cells, Cultured | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Interactions; Drug Synergism; Ganciclovir; Genetic Therapy; Glioma; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Simplexvirus; Temozolomide; Thymidine Kinase; Tumor Cells, Cultured | 2001 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therapy; Dacarbazine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Mice; Neoplasm Invasiveness; Protein-Tyrosine Kinases; Rats; Receptors, Vitronectin; Temozolomide; Tumor Cells, Cultured; Up-Regulation | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carrier Proteins; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA Repair Enzymes; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Glioma; Guanine; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Phenotype; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Temozolomide | 2002 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Cytarabine; Cytidine Diphosphate Diglycerides; Dacarbazine; Female; Glioma; Humans; Hydroxyurea; Infant; Lomustine; Male; Medulloblastoma; Methylprednisolone; Procarbazine; Vincristine | 1988 |